Document:

EX-10.11

 Exhibit 10.11 

EXECUTION VERSION 
 EMPLOYMENT
AGREEMENT 
 This Employment Agreement (this “Agreement”), dated as of February 21, 2019 (the
“Execution Date”), is entered into by and between TEVA PHARMACEUTICALS EUROPE B.V., a company incorporated under the laws of The Netherlands, Dutch Companies Register number 30110625 (“TPE” or
“Company”), and GIANFRANCO NAZZI, born on 30 June 1968, nationality _____, passport number ________ (the “Executive”). 

R E C I T A L S: 

WHEREAS, Executive has been employed by TPE on the basis of terms and conditions as inter alia laid down in a written employment contract
executed by Executive on 29 October 2013, as amended in Amendments/Addenda/Letters/Emails dated prior to 27 November 2017 and regardless whether those originated from TPE, TPI or any other Group Company (including without limitation, those
dated 2 December 2013 (on the Commencement Date), 19 February 2016 (on school fees), the letter dated 20 January 2017 (retention bonus) and 19 May 2017 (on eligibility to payments upon termination of employment)), which shall
jointly be referred to as the “Previous Employment Contract”. 
 WHEREAS, TPE desires to continue to employ the Executive and the
Executive has indicated his willingness to continue to provide his services to TPE on the terms and conditions set forth herein (the “Employment Contract”), which shall henceforward apply in substitution of the (terms and conditions of
the) Employment Contract; and 
 NOW, THEREFORE, on the basis of the foregoing premises and in consideration of the mutual covenants and
agreements contained herein, the parties hereto agree as follows: 
 1. Effective Date. This Agreement shall be effective as of
27 November 2017 (the “Effective Date”). The (terms and conditions of the) subject Employment Contract will, as from the Effective Date, and unless specifically stated otherwise in the subject Employment Contract,
substitute (all terms and conditions of) the Previous Employment Contract, with the exception of any provisions relating to outstanding cash retention awards dated 20 January 2017 and 18 September 2017, equity awards and the provisions on
relocation conditions as referred to in Section 5 (e) (i) hereof (which provisions hence will remain in force). 
 2. Term of
Employment. TPE hereby agrees to employ the Executive and the Executive hereby accepts such employment with TPE, on the terms and conditions hereinafter set forth. The term of employment (the “Term of Employment”) hereunder
shall be considered to have commenced on 1 February 2014 and shall continue for an indefinite term. 

 3. Position; Duties and Responsibilities; Place of Performance. 

(a) As from 27 November 2017, the Executive has been appointed as an Executive Officer of the Teva Group in the role of Executive Vice
President, Growth Markets Commercial which was subsequently renamed as International Markets Commercial (the “Role”). In such capacity, the Executive reports directly to the President and Chief Executive Officer of Teva Pharmaceutical
Industries, Ltd. (“TPI”). In addition, the Executive has such additional executive duties and responsibilities as may be assigned to him by the President and Chief Executive Officer of TPI. If the Executive is appointed as a
director or officer of TPI and/or any of its subsidiaries or affiliates (jointly: the “Teva Group” or the “Group Companies” and each severally a “Group Company”), the Executive shall serve in such capacity or capacities
without additional compensation. 
 (b) The Executive’s principal place of employment is at TPE headquarters in the Netherlands, except
that during the Relocation Term (as defined below) Executive’s principal place of employment shall be at TPI’s headquarters in Israel. The Executive understands and agrees that it is expected that the Executive will be required to travel
extensively (including internationally) in connection with the performance of his duties hereunder. 
 (c) Notwithstanding anything in this
Agreement to the contrary, the Executive, while outside of Israel, (i) shall not have authority to bind TPI and (ii) shall be subject to such further restrictions as to his activities on behalf of TPI or its subsidiaries as may be
determined by TPI from time to time. 
 (d) The Executive shall perform his duties under the Employment Contract on a full-time basis.
Executive shall be required to occasionally perform his duties during weekends and/or on public holidays, and/or outside regular office hours and/or in excess of the number of contractual working hours, if such is reasonably necessary for the proper
performance of the Executive’s duties under the Employment Contract (“Overtime”). Sufficient remuneration for Overtime shall be deemed included in the Base Salary and the Executive shall therefore not be entitled to any
(additional) remuneration for Overtime. 
 4. Exclusivity. Subject to the terms and conditions set forth in this Agreement, the
Executive shall devote his full business time, attention, and efforts to the performance of his duties under this Agreement and shall not engage in any other business or occupation during the Term of Employment, including, without limitation, any
activity that (a) conflicts with the interests of any Group Company, (b) interferes with the proper and efficient performance of his duties for TPI or TPE or (c) interferes with the exercise of his judgment in any Group Company’s
best interests. Notwithstanding the foregoing, nothing herein shall preclude the Executive from: (i) serving, with the prior written consent of the President and Chief Executive Officer of TPI, as a member of the board of directors or advisory
boards (or their equivalents in the case of a non-corporate entity) of non-competing businesses and charitable organizations; (ii) engaging in charitable activities
and community affairs; (iii) speaking at meetings of business, charitable and civic organizations; or (iv) subject to the terms and conditions set forth in Section 9 hereof, managing his personal investments and affairs;
provided, however, that the activities set out sub (i), (ii), (iii) and (iv) shall be limited by the Executive so as not to be in contradiction to any Group Company’s policy and/or materially interfere, individually or in the
aggregate, with the performance of his duties and responsibilities hereunder or create a potential business or fiduciary conflict. 

  
 2 

 5. Compensation and Benefits. 

(a) Base Salary. For services rendered under this Agreement, the Executive shall be entitled to a salary at the rate of EUR 447,000
gross per annum for the prorated period starting the Effective Date and ending 31 March 2018, and EUR 464,100 gross per annum for the period commencing 1 April 2018, including Dutch statutory holiday allowance (such salary, or any
increased salary granted to the Executive pursuant to this Section 5(a), the “Base Salary”), accruing on a pro rata tempore basis. The Executive’s Base Salary shall be payable in accordance with the payroll practices
of TPE as the same shall exist from time to time. The Human Resources and Compensation Committee (the “Compensation Committee”) of the Board of Directors of TPI (the “TPI Board”), with input from the
President and Chief Executive Officer of TPI, shall periodically consider and resolve whether to approve adjustments to the Executive’s Base Salary, according to the considerations specified in the shareholder-approved compensation policy of
TPI in effect from time to time (the “Compensation Policy”) and subject to approval of the TPI Board. 
 (b) Annual
Bonus. For each fiscal year that ends during the Term of Employment, the Executive shall be eligible to be considered for an annual bonus under the Company’s annual cash bonus plan in accordance with the Compensation Policy
(the “Annual Bonus”) and subject to the discretion of the Compensation Committee and the TPI Board. The Annual Bonus shall be paid to the Executive at the same time as annual bonuses are generally payable to other similarly
situated senior executives of TPE, subject to the Executive’s continuous employment through the payment date, except as otherwise set forth in this Agreement. As from the Effective Date, the Annual Bonus target will be 100% of the Base Salary
earned during the applicable year. 
 (c) Equity Awards. During the Term of Employment, the Executive shall be considered for
equity-based compensation awards under TPI’s 2015 Long-Term Equity-Based Incentive Plan or any successor equity compensation plan(s), at the sole discretion of the President and Chief Executive Officer of TPI, the Compensation Committee and the
TPI Board. Any such awards shall be granted on such terms and conditions as may be determined by the Compensation Committee and the TPI Board. 

(d) Benefits. 

(i) General. During the Term of Employment, the Executive shall be eligible to participate in such benefit plans and
programs (other than on (1) bonus (2) equity and (3) pension, since those benefits will be covered exclusively by the provisions of this Agreement) as shall be provided to similarly situated executives of TPE, subject to the terms and
conditions of such benefit plans and programs. Nothing contained herein shall be construed to limit TPE’s ability to amend, suspend, or terminate any employee benefit plan or policy at any time without providing the Executive notice, and the
right to do so is 

  
 3 

 
expressly reserved. The terms and conditions of any TPE Employee Handbook, as that handbook may read from time to time, will apply to the subject Employment Contract, albeit that any provision of
that handbook shall be considered superseded by the provisions explicitly stated or referred to herein. In case of discrepancies between the provisions of that handbook and provisions explicitly stated or referred to herein (including compensation
policies), the latter shall prevail and substitute the handbook-provisions. Any TPI or TPE codes of conduct and policies (other than those on (1) bonus (2) equity and (3) pension) shall fully apply to the subject Employment Contract. 

(ii) Pension. The Executive hereby explicitly waives any entitlement to participation in, and hence any entitlements to
accruals under, each and every company-pension scheme as operated by TPE (including, without limitation, both the basic ‘gross’ pension scheme arranging for certain pension accruals over the salary up to the cap set by Dutch wage tax
legislation and the ‘net’ pension scheme arranging for certain pension accruals over the salary in excess of that cap), with retro-active effect to the date of commencement of the Term of Employment. The Executive acknowledges and
understands that as a consequence of not participating in the TPE company-pension schemes, the Executive and/or his spouse/partner (i.e. partner pension) and/or children (i.e. orphan’s pension) have no rights/claims under the current
and/or future company-pension schemes of TPE against either TPE and/or the pension provider, which inter alia means that they will have no claims against TPE and/or the pension provider in case of
(e.g.): reaching any retirement age, the death of Executive before or after reaching any retirement age, sickness/incapacity for work of the Executive, divorce etc. At TPE’s request, the Executive will execute
each and every instrument required by TPE, or the pension provider, to (re-) confirm such waiver of rights. The Executive warrants that his spouse/partner will execute a written statement confirming his/her
consent to the Executive’s above-mentioned waiver and/or will execute a similar waiver(s) him/herself. In lieu of participation in any TPE-operated company-pension scheme (and provided that all of
the above waivers and further instruments required by TPE in that respect will be executed by both the Executive and his spouse/partner), the Executive will be entitled to a monthly gross allowance as well
as a monthly net allowance, each in the amount of the fictitious employer’s pension contributions (excluding premiums for any risk based insurances associated with those pension schemes) that would have
been contributed by TPE to the respective company-operated pension schemes if the Executive had participated in the TPE company-pension schemes (as those were and will be applicable from time to time). That
net allowance and the (net equivalent of the) gross allowance are intended for financing a private retirement scheme to be concluded and operated by the Executive and for financing any risk-based insurances for his own
benefit. Neither of these allowances will be considered to qualify as salary/income for the purpose of calculating any variable pay or for calculating the Lump Sum, transitional fee (statutory severance), value of accrued but
untaken holidays, VaBene or any other severance/damages/benefits to which the Executive may be entitled during or upon termination of the Employment. Parties acknowledge that Executive has received all such allowances in full in
respect of the period between the date of commencement of the Term of Employment and the Execution Date and that neither Party has any claims for over- or underpayment against the other Party in respect of the entitlement to allowances over that
period. 

  
 4 

 (iii) Vacation. During the Term of Employment, the Executive shall be
entitled to the same number of vacation days, holidays, sick days and other paid time off benefits as are generally allowed to other similarly situated executives of TPE in accordance with TPE’s policy as in effect from time to time. 

(e) Relocation.  

(i) General. From the Effective Date until 31 July 2022, and if such term is not approved by the Committee and the
Board then 31 May 2020 (the “Relocation Term”), the Executive will be entitled to (relocation) benefits in accordance with the terms of TPI’s 2015 Long Term International Assignment Policy (the “Relocation
Policy”), as shall be amended from time to time, and the terms of the Assignment Letter as executed by the Executive on 22 May 2017 (the “Assignment Letter”; Annex 2), to the extent relevant (i.e. to the extent
covering similar benefits) and to the extent allowed by the applicable laws, in substitution of benefits/entitlements which apply pursuant to clause 5(d) of the subject Employment Contract.  

(ii) Changes to Relocation Policy. The Executive acknowledges, agrees and understands that the Relocation Policy does
not form part of this Agreement and the Company reserves the right to amend, suspend, or terminate the Relocation Policy at any time without providing the Executive notice, and the right to do so is expressly reserved. Notwithstanding the foregoing,
(i) in the event of any conflict between the Relocation Policy and/or the Assignment Letter and this Agreement, the terms of this Agreement shall prevail, and (ii) the housing and education arrangements set forth in Executive’s
Assignment Letter may not be revised during Relocation Term without receiving Executive’s consent.  
 6. Ordinary Business
Expenses. During the Term of Employment, TPE shall reimburse the Executive for all reasonable out-of-pocket expenses incurred by the Executive in connection with the
business of the Teva Group and in the performance of his duties under this Agreement, including expenses for travel, lodging and similar items, all in accordance with TPE’s expense reimbursement policy, as the same may be modified from time to
time. TPE shall reimburse all such proper expenses upon the Executive’s presentation to TPE of an itemized accounting of such expenses with reasonable supporting data. 

  
 5 

 7. Termination of Employment. 

(a) General. The employment hereunder may be terminated by either party as per the last day of a calendar month, by giving written
notice to the other party. The Executive shall in that respect observe a notice period of three (3) months and TPE shall in that respect observe a notice period of six (6) months. 

(b) The date on which employment hereunder will formally terminate, shall be referred to in this Agreement as the “Termination
Date”. Upon the termination of the Executive’s employment hereunder for any reason, except as may otherwise be requested by the relevant Group Company in writing, the Executive shall resign from any and all directorships, committee
memberships or any other positions the Executive holds with any member of the Teva Group. For the avoidance of doubt, if the Executive’s employment with TPE will be terminated and be followed by employment between the Executive and any other
member of the Teva Group, the Executive will not be entitled to receive any of the severance benefits under this Agreement and any severance or other termination benefits the Executive may thereafter become entitled to receive (pursuant to the
subsequent employment with the other member of Teva Group) will be exclusively subject to the terms and conditions of any plan, program, policy or arrangement then in effect between the Executive and such other member of the Teva Group. 

(c) Death or Disability. The Executive’s employment shall terminate automatically upon his death (“Death”). In the event
the Executive’s employment is terminated due to his Death or for reasons of his Disability, the Executive or his estate or his beneficiaries, as the case may be, shall be entitled to (i) all accrued but unpaid Base Salary through the
Termination Date; (ii) any unpaid or unreimbursed expenses incurred in accordance with TPE policy, including amounts due under Section 6 hereof to the extent incurred prior to the Termination Date, to the extent due under the applicable
employment terms and/or mandatory applicable law; (iii) any other amounts required to be paid pursuant to applicable law, if any; and (iv) accrued and/or vested benefits under any plan or agreement covering the Executive which shall be
governed by the terms of such plan or agreement (items (i) through (iv) collectively, the “Accrued Obligations”). 

For purposes of this Agreement, “Disability” shall mean sickness/incapacity within the meaning of article 7:629 Dutch Civil
Code, exceeding the period during which the Executive can benefit from statutory protection against dismissal because of such incapacity. 

Except as set forth in this Section, following the Executive’s termination by reason of his Death or Disability, the Executive shall have
no further rights to any compensation or any other benefits under this Agreement. 
 (d) Termination by TPE for Cause. In the event of
termination of the Executive’s employment for Cause, he shall be entitled only to (A) all accrued but unpaid Base Salary through the Termination Date; and (B) any unpaid or unreimbursed expenses incurred in accordance with TPE policy,
including amounts due under Section 6 hereof to the extent incurred prior to the Termination Date. Following a termination of the Executive’s employment for Cause, except as set forth in this Section 7(d), the Executive shall have no
further rights to any compensation or any other benefits. 

  
 6 

 For purposes of this Agreement, “Cause” shall mean: termination of the
Executive’s employment hereunder through notice of termination issued by TPE for an urgent cause (dringende reden) within the meaning of article 7:677/678 Dutch Civil Code attributable to the Executive or at the initiative of TPE for
“serious culpable conduct or omission” (ernstig verwijtbaar handelen of nalaten) by the Executive within the meaning of article 7:673 para 7 intro and sub c Dutch Civil Code or “culpable conduct or omission”
(verwijtbaar handelen of nalaten) by the Executive within the meaning of article 7:669 para 3 intro and sub e Dutch Civil Code. 
 (e)
Termination by TPE without Cause. In case of termination of the Executive’s employment hereunder at the initiative of TPE without Cause, the Executive will –subject to the set-off and
conditions described below- be entitled to: 
 (i) The Accrued Obligations; 

(ii) A conditional gross payment (the “Lump Sum”), being the greater of: 

(1) the Dutch statutory severance (transitievergoeding) and a supplement thereto, up to in aggregate (i.e. statutory severance plus
supplement) 150% of the Executive’s Base salary; or 
 (2) the severance or damages to which the Executive would be entitled
under any TPE Social Plan, if and to the extent the Executive would have any eligibility under such Social Plan. 
 The Lump Sum will be set-off against (i.e. decreased by): any further compensation (vergoeding), including any billijke vergoeding and/or damages, as may be awarded to Executive in respect of the termination of the
employment hereunder, by a court in a ruling no longer subject to appeal. 
 Sixty-six percent (66%)
of the Lump Sum shall be payable within a reasonable time following Executive’s execution and delivery of the Release of Claims pursuant to Section 7(i) and thirty-four percent (34%) of the Lump Sum shall be payable, in 12 equal monthly
installments, with reasonable time following Executive’s execution and delivery of the Release of Claims pursuant to Section 7(i). 

The entitlement to the payments and benefits described in subsection 7.e.(ii) (i.e. the Lump Sum after
set-off, if applicable) shall, to the extent exceeding the benefits/payments to which Executive would be entitled in respect of the termination of the employment pursuant to (Dutch) statute or a court ruling
which is no longer subject to appeal, be subject to Executive fully complying with the obligations arising from Section 9 hereof. In the event that the Executive breaches any provision of Section 9 hereof, the entitlement to such excess
payments and benefits under subsection 7.e.(ii) shall immediately cease, which means that the Company shall have no further obligations to the Executive with respect thereto, and the Executive shall 

  
 7 

 
promptly repay to TPE any payments or benefits paid or provided to the Executive pursuant to subsection 7.e.(ii) , in as far as those payments/benefits exceed the benefits/payments to which
Executive would be entitled in respect of the termination of the employment pursuant to (Dutch) statute or a court ruling which is no longer subject to appeal. 

Following a termination of the Executive’s employment at the initiative of TPE without Cause, except as set forth in this
Section 7(e), the Executive shall have no further rights to any compensation or any other benefits under this Agreement. 
 For
purposes of this Agreement, a termination of the Executive’s employment hereunder at the initiative of TPE “without Cause” shall mean: a termination of the Executive’s employment hereunder at the initiative of TPE on any ground
other than Death, Disability or “(for) Cause”. 
 (f) Resignation. In the event of termination of Executive’s
employment hereunder through a termination notice (opzegging) issued by the Executive (resignation) or through a court rescission (ontbinding) of the Executive’s employment hereunder upon a petition made by the Executive, the
Executive shall be entitled to the Accrued Obligations and, unless TPE were to release the Executive from the non-compete restrictions included in Section 9 sub (d) hereof in its sole discretion, an
amount equal to the Annual Base Salary accruing and payable in 12 monthly instalments, subject to the Executive compliance and continuing compliance with the restrictions pursuant to Section 9 hereof and following the Executive’s execution
and delivery and non-revocation of the Release of Claims pursuant to Section 7(i). 
 (g) In the
event of the termination of the Executive’s employment, TPE may, in its sole and absolute discretion, by written notice, waive the services of the Executive during any applicable notice period or in respect of any part of such period, all on
the condition that TPE will pay the Executive the monthly Base Salary and all additional compensation and benefits to which the Executive is entitled in respect of the applicable notice period (including but not limited to relocation benefits, the
extent applicable) without regard to any such TPE waiver, albeit not including compensation pursuant to Section 5(b) and 5 (c) hereof). 

(h) Change of Control. In the event that the Executive’s employment is terminated at the initiative of TPE, during the one year
period following a merger of TPI with another (non-Teva Group) entity, pursuant to which merger TPI is not the surviving entity, and such termination is both “without Cause” and a result of such
merger, then, in addition to any payments or other benefits to which the Executive is entitled pursuant to this Section 7, the Executive shall also be entitled to receive a lump sum cash payment in an amount equal to USD 1,500,000 gross,
payable on the next regular payroll date immediately following the sixtieth (60th) day after the Termination Date. 

  
 8 

 (i) Final Discharge. Notwithstanding any provision herein to the contrary, the
payment of any amount or provision of any benefit pursuant to this Section 7 other than the Accrued Obligations (collectively, the “Severance Benefits”) shall be conditioned upon and be payable within a reasonable time
after the Executive’s execution, delivery to TPE, and non-revocation of a statement of full and final discharge of any claims Executive has or may have pursuant to the employment hereunder and/or the
termination of such employment (the “Release of Claims”) within sixty (60) days following the Termination Date. If the Executive fails to execute the Release of Claims within sixty (60) days following the Termination
Date, the Executive shall not be entitled to any of the Severance Benefits. For the avoidance of doubt, in the event of a termination by reason of the Executive’s Death or Disability, the Executive’s obligations herein to execute the
Release of Claims may be satisfied on his behalf by his estate or a person having legal power of attorney over his affairs. 
 (j)
Compliance with Covenants. The Executive’s entitlement to the Severance Benefits, to the extent those Severance Benefits exceed the statutory minimum to which the Executive may be entitled under Dutch law, will be subject to the
Executive’s full compliance with any and all of the restrictions included in or referred to in Section 9 hereof, without prejudice to any other remedies available to the Company hereunder and/or pursuant to applicable law, and the
Executive shall promptly repay to TPE any Severance Benefits (to the extent exceeding Executive’s statutory minimum entitlements) paid or provided to the Executive pursuant to this Section 7 prior to the date of any breach of any of the
restrictions included in or referred to in Section 9 hereof and the Executive’s entitlement to any as yet unpaid Severance Benefits (including without limitation the Executive’s entitlement to the Restriction Compensation) will cease
as from the date of such breach. 
 (k) Return of Property. Upon termination of the Executive’s employment, the Executive shall
promptly return to TPE any cell phone, laptop or other hand-held device provided by any Group Company to the Executive, and any confidential or proprietary information of any Group Company that remains in the Executive’s possession;
provided, however, that nothing in this Agreement or elsewhere shall prevent the Executive from retaining and utilizing documents relating to his personal benefits, entitlements and obligations; documents relating to his personal tax
obligations; his desk calendar, personal contact list, and the like; and such other records and documents as may reasonably be approved by the TPE Board or the President and Chief Executive Officer of TPI. 

8. Representations. The Executive hereby represents that (a) he is legally entitled to enter into this Agreement and to perform the
services contemplated herein and is not bound under any employment, consulting or other agreement to render services to any third party, (b) he has the full right, power and authority, subject to no rights of third parties, to grant to the
relevant Group Companies the rights contemplated by Section 9(b) hereof, and (c) he does not now have, nor within the last three (3) years has he had, any ownership interest in any business enterprise (other than interests in publicly
traded corporations where his ownership does not exceed one percent (1%) or more of the equity capital) which is a customer of the Teva Group, or from which the Teva Group purchases any goods or services or to whom any Group Companies owes any
financial obligations or is required or directed to make any payments. 

  
 9 

 9. Executive’s Covenants. 

(a) Disclosure of Information. The Executive recognizes and acknowledges that the trade secrets,
know-how and proprietary information and processes of Teva Group, as they may exist from time to time, are valuable, special and unique assets of the business of the Teva Group, access to and knowledge of
which are essential to the performance of the Executive’s duties hereunder. The Executive will not, during or at any time following the Term of Employment, in whole or in part, disclose such secrets,
know-how or processes to any person, firm, corporation, association or other entity for any reason or purpose whatsoever, nor shall the Executive make use of any such secrets,
know-how or processes for his own purposes or for the benefit of any person, firm, corporation or other entity (except for a member of the Teva Group) under any circumstances during or after the Term of
Employment; provided, that, after the termination of his employment, these restrictions shall not apply to such secrets, know-how and processes which are then in the public domain (provided that the
Executive was not responsible, directly or indirectly, for such secrets, know-how or processes entering the public domain without TPE’s consent). In addition, nothing contained in this Agreement shall be
construed to prohibit the Executive from reporting possible violations of federal or state law or regulation to any governmental agency or regulatory body or making other disclosures that are protected under any whistleblower provisions of federal
or state law or regulation, or from filing a charge with or participating in any investigation or proceeding conducted by any governmental agency or regulatory body. 

(b) Inventions. The Executive hereby sells, transfers and assigns to TPE, or to any person or entity designated by TPE, without any
rights whatsoever to additional compensation all of the entire right, title and interest of the Executive in, and to, all inventions, ideas, disclosures and improvements, whether patented or unpatented, and copyrightable material, made or conceived
by the Executive, solely or jointly, during the Term of Employment, which relate to methods, apparatus, designs, products, processes or devices, sold, leased, used or under consideration or development by any Group Company, or which otherwise relate
to or pertain to the business, functions or operations of any Group Company or which arise from the efforts of the Executive during the course of his employment for any Group Company. The Executive shall communicate promptly and disclose to TPE, in
such form as TPE requests, all information, details and data pertaining to the aforementioned inventions, ideas, disclosures and improvements. The Executive shall execute and deliver to TPE such formal transfers and assignments and such other papers
and documents as may be necessary or required of the Executive to permit TPE or any person or entity designated by TPE, to file and prosecute the patent applications and, as to copyrightable material, to obtain copyright thereof. Any invention
relating to the business of any Group Company made by the Executive within one year following the termination of the Term of Employment shall be deemed to fall within the provisions of this paragraph unless proved to have been first conceived and
made following such termination. The Executive’s remuneration under this Employment Contract shall be considered to include ample and sufficient remuneration in respect of the Executive’s involvement in the conception or making of any and
all of the inventions, ideas, disclosures and improvements referred to in this clause and the Executive shall hence not be entitled to any additional remuneration in respect of his involvement in their conception or making. 

  
 10 

 (c) Covenant Not to Interfere. During the Term of Employment and for a period of
twelve (12) months following the Termination Date, the Executive shall not, directly or indirectly, (i) solicit or induce, or in any manner attempt to solicit or induce, any person employed by, or engaged as agent of, any Group Company to
terminate such person’s contract of employment or agency, as the case may be, with such Group Company or (ii) divert, or attempt to divert, any person, concern or entity from doing business with any member of Teva Group, or attempt to
induce any such person, concern or entity to cease being a customer or supplier of any Group Company. 
 (d) Covenant Not to Compete.
By signing this Agreement, the Executive hereby acknowledges and agrees that, in his Role, the Executive will have a great deal of exposure and access to a broad variety of commercially valuable proprietary information of the Teva Group, including,
by way of illustration, confidential information regarding the Teva Group’s current and future products and strategies, costs and other financial information, R&D and marketing plans and strategies, etc. As a result of the Executive’s
knowledge of the above information and in consideration for the benefits offered by TPE under this Agreement, the Executive affirms and recognizes his continuing obligations with respect to the use and disclosure of confidential and proprietary
information of the Teva Group pursuant to the Teva Group’s policies and the terms and conditions of this Agreement, and hereby agrees that, during the Term of Employment and for a period of twelve (12) months following the Termination Date
, the Executive shall not, directly or indirectly (whether as an officer, director, owner, employee, partner, consultant or other direct or indirect service provider) work for or perform any services for any company or group of companies, which is
focused on the development, manufacture of, sale of or trading in (i) generic products or (ii) specialty pharmaceutical products that are competitive with a fundamental product developed, manufactured, sold or otherwise traded in by Teva
Group as of the date of such termination of employment, where the determination of whether a certain product constitutes a fundamental product developed, manufactured, sold or otherwise traded in by the Teva Group shall be reasonably determined on
an ad-hoc basis at the relevant time by the President and Chief Executive Officer of TPI. These restrictions shall apply world-wide, i.e. regardless of where the work or services would be performed by the
Executive and regardless of where the relevant (division, subsidiary or product group of the) company or group of companies would be located or would be doing business. 

(e) Non-Disparagement. During the Term of Employment and at all times thereafter, the Executive
agrees not to (i) make any disparaging or defamatory comments regarding any member of the Teva Group or any of its current or former directors, officers, employees or products or (ii) make any negative or disparaging comments concerning
any aspect of the Executive’s relationship with any member of the Teva Group or any conduct or events relating to any termination of the Executive’s employment with TPE. 

  
 11 

 (f) Cooperation. During the Term of Employment and at all times thereafter, the
Executive agrees to cooperate with the Company and its attorneys in connection with any matter related to the period he was employed by TPE and/or his services to other members of the Teva Group, including but not limited to any threatened, pending,
and/or subsequent litigation, government investigation, or other formal inquiry against ant member of the Teva Group, and shall make himself available upon notice to prepare for and appear at deposition, hearing, arbitration, mediation, or trial in
connection with any such matters. Such cooperation will include willingness to be interviewed by representatives of any Group Company and to participate in legal proceedings by deposition or testimony. 

(g) Blue Pencil. It is the desire and intent of the parties that the provisions of this Section 9 be enforced to the fullest extent
permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought. Accordingly, if any particular provision or clause of this Section 9 shall be adjudicated to be invalid or unenforceable or overly broad
in scope, time or geographic region, then such provision or clause shall be deemed amended to delete therefrom the portion thus adjudicated to be invalid or unenforceable or to reduce or narrow down the portion thus adjudicated to be too broad in
scope, time or geographic region, such deletion, reduction or narrowing down to apply only with respect to the operation of this Section 9 in the particular jurisdiction in which such adjudication is made. 

(h) Injunctive Relief. If there is a breach or threatened breach of the provisions or clauses of this Section 9, TPE shall be
entitled to an injunction restraining the Executive from such breach. Nothing herein shall be construed as prohibiting TPE from pursuing any other remedies for such breach or threatened breach. 

10. Insurance. TPE may, at its election and for its benefit, insure the Executive against death, and the Executive shall submit to such
physical examination and supply such information as may be reasonably required in connection therewith. 
 11. Clawback. All payments
made pursuant to this Agreement are subject to the “clawback” provisions in the Compensation Policy. 
 12. Required Stock
Ownership. The Executive acknowledges and agrees to adhere to the TPI’s stock ownership guidelines applicable to senior executives of TPI and/or TPE, as may be amended from time to time in TPI’s sole discretion. 

13. No-Hedging Policy. The Executive acknowledges and agrees to adhere to the TPI’s No-Hedging Policy applicable to senior executives of TPI and/or TPE, as may be amended from time to time in TPI’s sole discretion. 

14. No-Pledging Policy. The Executive acknowledges and agrees to adhere to the TPI’s No-Pledging Policy applicable to senior executives of TPI and/or TPI, as may be amended from time to time in TPI’s sole discretion. 

  
 12 

 15. Notices. Any notice required or permitted to be given under this Agreement shall
be deemed sufficient if in writing and if demonstrably received by the Executive and TPE or TPI respectively. 
 16. Waiver of Breach.
A waiver by the Company or the Executive of a breach of any provision of this Agreement by the other party shall not operate or be construed as a waiver of any subsequent breach by the other party. 

17. Governing Law; Severability. This Agreement shall be governed by and construed and enforced in accordance with the laws of The
Netherlands without giving effect to the choice of law or conflict of laws provisions thereof. Whenever possible, each provision or portion of any provision of this Agreement will be interpreted in such manner as to be effective and valid under
applicable law but the invalidity or unenforceability of any provision or portion of any provision of this Agreement in any jurisdiction shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the
validity or enforceability of this Agreement, including that provision or portion of any provision, in any other jurisdiction. In addition, should a court determine that any provision or portion of any provision of this Agreement, is not reasonable
or valid, either in period of time, geographical area, or otherwise, the parties agree that such provision should be interpreted and enforced to the maximum extent which such court deems reasonable or valid. 

18. Taxes. The Company may withhold from any payments made under this Agreement all applicable taxes, including but not limited to
income, employment, payroll taxes and social insurance charges/taxes, as shall be required by applicable law. 
 19. Assignment. This
Agreement may be assigned, without the consent of the Executive, by TPE to any member of the Teva Group or to any person, firm, partnership, corporation or other entity that has purchased all or substantially all the assets of TPE and/or TPI;
provided, that such assignee assumes any and all of the obligations of TPE hereunder. TPE or, if applicable, TPI shall cause any person, firm, partnership, corporation or other entity acquiring all or substantially all of the assets of TPE
respectively TPI to execute a written instrument agreeing to assume any and all of the obligations of TPE hereunder as a condition to acquiring such assets. 

20. Compensation Policy. This Agreement shall be subject to the Compensation Policy and nothing herein shall derogate in any way from
the Company’s rights thereunder. 
 21. Entire Agreement; Amendment. This Agreement contains the entire agreement of the parties
and supersedes any and all agreements, letters of intent or understandings between the Executive and (a) TPE, (b) TPI, (c) any other Group Company or (d) any of TPI’s principal shareholders, except for applicable provisions
of the Assignment Letter, the 14 December 2017 Letter, cash retention awards dated January 20, 2017 and September 18, 2017, equity compensation plans, policies, and other separate agreements, plans and programs explicitly referred to
herein; provided, that this Agreement shall not alter the Executive’s obligations to any 

  
 13 

 
member of the Teva Group under any confidentiality, invention assignment, or similar agreement or arrangement to which the Executive is a party with any member of the Teva Group, which
obligations shall remain in force and effect. Notwithstanding the foregoing, in the event of any inconsistency between the provisions of this Agreement and the (provisions of the) Compensation Policy, the terms of the Compensation Policy
shall prevail/control. TPE is entitled to unilaterally amend the employment conditions (arbeidsvoorwaarden) under this Employment Contract whether included in this instrument, or any TPE or TPI policies, whether referred to in this instrument
or not, with due observance of the provisions of article 7:613 and/or 7:611 Dutch Civil Code. 
 22. Headings. The headings of the
sections and subsections contained in this Agreement are for convenience only and shall not be deemed to control or affect the meaning or construction of any provision of this Agreement. 

23. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which
together shall be considered one and the same agreement. Signatures delivered by facsimile or by e-mail as a portable document format (.pdf) file or image file attachment shall be effective for all purposes.

 24. Survival. The provisions of this Agreement that are intended to survive the termination of this Agreement shall survive such
termination in accordance with their terms. 
 25. Indemnification. The Indemnification and Release Agreement between TPI and the
Executive, dated November 27, 2017, shall continue to apply in full force and effect in accordance with its terms, and is incorporated by reference to this Agreement. 

26. No Collective Bargaining Agreement. TPE is not bound by any collective bargaining agreement and no collective bargaining agreement
applies to the Executive’s employment hereunder. 

*            *           
  * 
 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date specified in the first paragraph of this Agreement.

  
 14 

 
			
	TPE.
		
	By:	 	 /s/ Niels Walch

		 	Name: Niels Walch
		 	Title: SVP, HR Europe
		
	By:	 	 /s/ David Vrhovec

		 	Name: David Vrhovec
		 	Title: CFO Europe
	
	EXECUTIVE
	
	 /s/ Gianfranco Nazzi

	Gianfranco Nazzi
	EVP, International Markets
	Tel Aviv, 1/4/2019

  
 15 

  
 

 
 Private & Confidential 

March 15, 2017 
 To: Gianfranco Nazzi 

Dear Gianfranco, 
 Reference: Your Home
Based Long Term International Assignment 
 Congratulations on your assignment. Global Mobility is an important part of Teva’s growth,
globalization, and talent initiatives. We believe that international assignments help Teva achieve worldwide business targets while simultaneously developing employee’s capabilities and international business experience. We hope that you will
benefit both personally and professionally from your experience. This letter summarizes the general terms and conditions of your assignment with Teva. 

ASSIGNMENT SUMMARY 
  

			
	Home Country:	 	The Netherlands
	Host Country:	 	Israel
	Employer (Legal Entity):	 	Teva Pharmaceuticals Europe BV
	 Host Site Entity:

Annual Base Salary: 
	 	 Teva Pharmaceutical Industries Ltd

442,000.00 EUR

	Bonus Guideline:	 	60%
	 Position Title:

Grade:
	 	 President & CEO Growth Markets

21

	Citizenship/Permanent Resident Status:	 	Italy
	Manager While on Assignment:	 	Dipankar Bhattacharjee
	Estimated Assignment Start Date*:	 	June 01st , 2017
	Scheduled Assignment End Date:	 	May 31st , 2020
	 Assignment Policy:

Home or Host based Assignment:

International Assignment Policy Date:
	 	 2015 Long Term International Assignment

Home Based Assignment
 April 2015

	
Family Size at Host (including Employee):
	 	5

  

	*	 Your actual effective date of assignment will be determined following receipt of your authorization to work and
reside in the Host country. 

 This letter does not create a contract of employment, but simply seeks to confirm the conditions which
pertain to your temporary international assignment. Should the nature of your position change or if this assignment extends beyond its initial duration} the terms may be subject to change at that time. Teva reserves the right to modify the global
assignment policies and procedures at any time in whole or in part, with or without notice. 

  
 1 

 COMPENSATION 

As a Home Based assignee, it is the intention of the Teva International Assignment policy to provide you with a compensation package derived from what you
would receive as an employee based in your home country. You will continue on the Annual Increment Policy of the home country based on your performance. It is Teva’s intention to pay your compensation via your Home Company’s payroll into
your home country bank account in the home country currency. When required per local host regulations however, you may be paid a portion or all of your compensation in the host country. When your assignment ends, all assignment benefits and
allowances will cease. During your assignment if applicable and according to your Home country manager’s sole discretion, your base salary will be reviewed and adjusted according to your home country policies. 

ANNUAL INCENTIVE COMPENSATION 
 Any incentive compensation
eligibility (e.g., cash bonus, stock option, restricted stock units, etc.) is in accordance with Teva’s incentive compensation plans and programs as they may be amended from time to time. Incentive compensation paid in the form of cash, if any,
will be paid from your home country payroll. 
 BONUS 

Over the current performance year 2017 respectively and thereafter you will have the opportunity to earn an on-target
bonus of 60% as stated above, payable in March/April of the following calendar year. Superior performance may be rewarded above that on-target level, subject to management discretion. Any bonus earned will be
paid from your home country payroll. 
 BENEFITS 
 You
and your dependents will participate in the International Benefits Plan for medical, dental, long-term disability, group life and accidental death & Dismemberment insurance coverage. Currently medical and dental coverage in Israel is
provided through David Shield International Medical Insurance an insurance provider that specializes in international benefits. Medical coverage is provided in two ways: 
  

	 	i.	 By using the network of the “health fund” used by David Shield and under this system there is a
direct billing arrangement between the doctor and the insurance company 

  

	 	ii.	 Through a fee-for-service
medical plan in which you select whichever doctor or hospital you want to use. You pay for services up-front, and then submit claims to David Shield for reimbursement of the covered medical expenses –
currently at 80%. Dental coverage is provided through David Shield via dental clinics associated with them. This is a comprehensive dental plan which pays 100% for certain treatments and the insured pays a subsidized contribution to more advanced
treatments. 

 VISA/IMMIGRATION 
 It
is important that you have the required documentations to legally work and reside in the host country; our professional immigration partner will be authorized to assist you. Relocation to your new host location must not take place until your work
authorization is received. The terms of this Letter of Assignment shall not come into, or remain in force, unless and until you are granted any necessary visas or work permits allowing you to live and work in the host. Necessary costs incurred to
obtain your authorization to work and your spouse’s and dependents authorization to reside in the host country will be managed by Teva’s global relocation provider. 

  
 2 

 Teva supports only required documentation for the intended assignment duration and will not provide
financial assistance towards the acquisition of permanent resident status or documentation. 
 PRE-ASSIGNMENT
TRIP 
 If necessary, to help you become familiar with the assignment location, house hunting trip of up to 5 days will be authorized for you and your
spouse and 3 children. During this time, you will receive a per diem in accordance with the Teva Business Travel policy to cover reasonable costs of meals and incidentals. Ground transportation, lodging and air travel (booked at least 14 days in
advance via the most direct route) will be provided in accordance with The Teva Travel policy. Reimbursement must be claimed via your usual home country travel expense process. 

SHIPMENT OF HOUSEHOLD GOODS 
 Teva provides assistance
with the shipment of personal effects, as well as the cost of packing, loading, inland transportation, and customs or import duties up to established limits. 

For immediate needs, excess baggage is reimbursed. Household goods may be shipped via sea or overland container. 

Excess Baggage Limits (Unaccompanied and Accompanied) 

Three (3) excess bags for each relocating family member. 

Surface Shipment Limits (Accompanied only) 

40 ft. (68 m3) container for assignees with a total family size of 4 or greater. 

Insurance 
 Teva insures
against damage to or losses from the goods shipment, exclusive of those items not approved for shipment up to limits established by the shipping provider. 

Storage (Unaccompanied and Accompanied) 

Teva provides temporary storage support in cases where your household goods shipment arrives in the receiving location before permanent
housing is available (e.g. during the temporary living period). Any other storage needs in your home country or in your host country is your responsibility. 

Pets (Unaccompanied and Accompanied) 

Teva does not cover pet shipment costs. 
 All
approved costs will be paid directly by Teva’s global relocation provider. 
 Please note that Teva does not cover costs for the shipment of items
restricted by the government or other regulations, or any items that are excessively large, high value, or perishable, or that require special care. The following is a representative list (this list does not include all prohibited items): alcohol,
appliances, automobiles, boats, building materials/shop equipment, firearms/ammunition, furs/jewelry/fine art/antiques, hot tubs, lawnmowers, motorcycles, pianos, plants, and RVs/campers. 

  
 3 

 HOME COUNTRY HOUSING – LEASE CANCELLATION 

Teva reimbursement up to two (2) months’ rent incurred as a penalty due to lease cancellation. Reimbursement DOES NOT include loss of security
deposit due to neglect, damage, or loss of a pet/smoking deposit. In order to claim reimbursement proper documentation must be provided to Teva’s designated dedicated relocation provider 

TRAVEL TO THE HOST LOCATION 
 On your relocation trip to
your new Host Country, Teva will pay the cost of travel for you (and your spouse/dependents) including airfare, ground transportation, and in-transit living expenses. Travel class is based on Teva’s
Business Travel policy, booked at least 30 days in advance via the most direct route. This cost should be booked via Teva’s travel provider and expenses claimed via Teva’s dedicated relocation provider. 

DESTINATION SERVICES 
 A provider designated by Teva will
assist with house hunting and the coordination of a variety of settling-in services, e.g. local registrations, banking, and utility connections. 

TEMPORARY LIVING 
 You will be provided Temporary Living
for up to 30 days after vacating your residence in your Home Country and prior to establishing residence in your new Host Country. Your per diem will be 75 EUR net per person per day. (Children under the age of 14 will receive 50% of this amount).
If needed, you will also receive car rental for this period. The per diem will be paid to you by Teva’s dedicated relocation provider and car rental (if applicable) will arranged by Teva’s relocation provided and paid directly on your
behalf. 
 RELOCATION ALLOWANCE 
 To cover any
individual costs not specifically covered in the assignment policy, you will receive a Miscellaneous Relocation allowance equivalent to 4,691 EUR. This payment will be processed by the dedicated relocation provider in advance of your departure from
the Home Country or upon arrival in the Host country whichever you prefer. You will receive the full amount listed above and Teva is responsible for any applicable taxes. 

SPOUSAL ASSISTANCE ALLOWANCE 
 Teva does not compensate
for the loss of spousal/partner income as a result of the assignment but rather recognizes that the financial impact exists. To ease the transition, Teva reimburses for job placement and related services if your spouse accompanies you full time on
assignment. Maximum reimbursement is equivalent to 1,876.00 EUR. Reimbursement must be claimed within 12 months of the effective date of your assignment and Teva is responsible for any applicable taxes. Reimbursement will be processed by Teva’s
dedicated relocation provider. 
 LIFESTYLE ALLOWANCE 

To recognize the fact that you (and your spouse/family) have different needs that may not be covered elsewhere in the policy, you will receive a one-time allowance equivalent to 2,815.00 EUR net payable upon your first anniversary of this assignment. This payment will be processed by Teva’s dedicated relocation provider and Teva is responsible for any
applicable taxes. 

  
 4 

 COST LIVING ALLOWANCE 

A cost of living allowance may be provided in those circumstances where the cost of a representative market basket of goods and services (excluding housing,
taxes, education and auto purchase) in the host country location exceeds the cost of the same or similar basket of goods and services in the home country location. COLA is analyzed by an independent statistical data provider and considers both the
price of the market basket as well as the effect of currency fluctuations on purchasing power. If a COLA is applicable, it will be paid to you each pay period. The amount will be reviewed periodically, but at least semi-annually and adjusted, up or
down, at the discretion of the Company. You will be advised of any changes prior to its implementation. Based on your salary level, family size and current statistical data, you are eligible for a monthly COLA payment of: 

 

			
	Current monthly Goods & Services Allowance	  	2,551.17 EUR per month NET

 This payment is payable by Teva’s payroll and Teva will cover any related taxes. 

LANGUAGE LESSONS 
 Your ability to speak and understand
the host language will increase business effectiveness and expedite social integration in the host location. If needed, you and your spouse will each be provided up to 100 hours of language instruction which will be coordinated by Global Mobility.
When considering schools for your children, please consider any host language needs as the cost for language lessons for your school aged children are your responsibility. Teva’s dedicated relocation provider will arrange language lessons on
your behalf and all related costs will be covered by Teva through the relocation provider. 
 INTERCULTURAL ORIENTATION 

To help you acclimate to the host country’s culture and environment both from a business and a social perspective, Teva provides a one-day mandatory Intercultural Orientation for you and your spouse. All arrangements for this training will be coordinated by Teva’s dedicated Relocation Provider and Teva will pay all related expenses
directly. 
 Following your training and during your assignment, you will have the ability to utilize Teva’s internal Cross-Cultural training located
on the Teva’s intranet. You may access the site through this link: http://tevanet.teva.corp/global/EN/Campiagns/Pages/Introducing-GlobeSmart.aspx. 

HOUSING ALLOWANCE 
 Teva will pay for suitable
accommodation costs in your host country for the duration of your assignment, with a monthly housing allowance of 32,000 ILS, net. The housing allowance will be provided in services only and not cash. A provider designated by Teva will assist you
with the arrangements to ensure that your lease agreement includes a lease break clause and that you do not sign a document that binds you to unnecessary liability. If you select housing above your maximum rental budget, the overage is your
responsibility. Teva will also pay for security and lease deposits required by the lease agreement. At the end of your assignment, these funds are to be refunded to you by the landlord. Whether or not your deposits are refunded, you are responsible
for returning the funds to Teva. It is highly recommended that you insure your personal household items. The cost for Renter’s insurance is your responsibility. Your housing will be paid directly by Teva’s designated provider to your
landlord or to you for payment to your landlord. 

  
 5 

 Please note that if you purchase your primary residence in the host country, your housing allowance will
immediately cease. 
 HOST AUTOMOBILE BENEFIT 

Any entitlement is strictly based on the host company car policy. All arrangements will be coordinated by your Host country HR representative. 

EDUCATION ALLOWANCE 
 Teva will cover the cost and related
taxes of local or international schooling for accompanying dependent children meeting compulsory school age. Teva will cover costs which are reasonable, as determined by the provider designated by Teva. Teva will cover the following expenses, which
are paid directly to the school: tuition, enrollment fees and mandatory administration fees. Any other education related fees will not be covered. Nursery School and Daycare are not covered. Payment of school fees will be made directly to the school
by Teva’s dedicated relocation provider or to you for payment to the school, whichever is more cost effective for Teva. 
 HOME LEAVE BENEFIT

 You will be provided one home leave every 12 months on assignment between your home country and your host country for you and your
spouse/partner/dependents who live with you full time in the host country. Teva covers round trip airfare, based on economy fare booked at least 30 days in advance and via the most direct route. Any ground transportation and/or lodging costs are
your responsibility. You must use your vacation time for your home leave visits and the time away must be approved by your manager. Reimbursement will be claimed via Teva’s dedicated relocation provider. 

HOURS OF WORK, HOLIDAY, & VACATION 
 While on
assignment you will follow the nationally recognized paid holiday schedule of the host location and your vacation benefit continues in accordance with your home guidelines except where host country labor laws require otherwise. Your vacation time
must be approved by your direct manager. 
 EMERGENCY ASSISTANCE/EVACUATION 

In instances of political or civil emergency affecting an employee on an international assignment, it is the primary objective of Teva to ensure the safety and
welfare of the employee and accompanying dependents. Please notify your Host Country Human Resources department and Global Mobility of all actual or potentially serious emergencies so that appropriate steps may be taken. 

PENSION & SOCIAL SECURITY 
 To the extent
possible, you remain on the home country pension/retirement plan and contribution schedule and your home social security scheme through regular payroll deductions. In cases where the home country pension/retirement plan cannot be maintained through
the usual or voluntary contributions while on assignment, you may be able to participate in the host country scheme or Teva will arrange for you to participate in an alternative scheme. In some host locations, contributions to social tax schemes are
mandatory and when that is the case, Teva will meet any mandatory host country employer and employee contributions on your behalf. 

  
 6 

 TAX POLICY 

You will be under the Teva tax equalization policy during your assignment. The intent of this policy is that your ultimate tax liability will be similar to
that which you have paid in the Home Country on your regular compensation had you not received assignment-related compensation or special tax considerations. Under this policy: 

 

	 	•	 	 you will be responsible for a hypothetical tax liability on both income and social taxes, which will be
calculated and deducted from each paycheck, 

  

	 	•	 	 Teva will be responsible for an excess tax liability in the host country, and 

 

	 	•	 	 it is your responsibility to pay income taxes in the home country (although covered by Teva)

 The extent of this tax coverage by Teva is limited to your Teva compensation including salary, bonus, benefits and earnings related to
equity that is vested while you are on assignment, but does not include earnings that you receive outside of your employment with Teva. The intent of the policy is that your ultimate tax liability will be similar to the amount you would have paid in
the home country on your regular compensation had you not received assignment-related compensation or special tax considerations. Each year, a final tax equalization calculation will be prepared to settle your assignment tax obligations. 

TAX PREPARATION AND SERVICES 
 It is a condition of
employment that you comply with all personal tax responsibilities for each taxing authority in which a responsibility exists. The responsibility includes the proper filing of all tax returns. You are also responsible for notifying Teva of the tax
payments due. The Company has retained the services of a Tax Consultant to prepare your home country and host country tax returns as required during the assignment period. Although you are fully responsible for the payment of all applicable income
taxes and tax duties while on assignment, the Company will directly pay the consultant tax preparation and consulting fees on your behalf. Contact information of the Tax Consultant will be provided to you prior to the commencement of your assignment
so that you may discuss your particular tax preparation needs in detail. Tax preparation assistance is limited to your filing and only extends to a spouse/partner when filing jointly. The Company will directly pay the consultant tax preparation and
consulting fees on your behalf. Costs associated with personal financial planning will be your responsibility. 
 CHANGE IN TEVA’S INTERNATIONAL
ASSIGNMENT POLICY DURING ASSIGNMENT 
 This Letter of Assignment has been prepared by referencing Teva’s International Assignment Policy (the
policy). The policy does not form part of the Letter of Assignment and Teva reserves the right to vary the policy and associated benefits from time to time. You will be notified of any such variations or amendments to the policy and the impact on
your arrangements. Where the provisions of the policy differ from those in this Letter of Assignment, the terms set out in this letter shall prevail. 

EARLY TERMINATION OF INTERNATIONAL ASSIGNMENT 
 In the
event Teva, in its sole discretion, ends your international assignment before its scheduled end date, Teva will provide return trip airfare for you and your dependents back to the point of origin, and will ship household goods back to the point of
origin or to some other mutually agreed upon location. Unless otherwise agreed to by regional management and Human Resources, the return must be completed within 60 days after the effective date of the termination of the international assignment. By
failing to relocate within 60 days, you forfeit Teva’s offer to pay for repatriation transportation costs. 
 INVOLUNTARY TERMINATION OF EMPLOYMENT

 In the case of an involuntary termination of employment with Teva, Teva will provide return trip airfare for you and your dependents back to the point
of origin, and will ship household goods back to the point of origin or to some other mutually agreed upon location. Unless otherwise agreed to by regional management and Human Resources, the return must be completed within 60 days after the
effective date of the termination of employment. By failing to relocate within 60 days, you forfeit Teva’s offer to pay for repatriation transportation costs. 

  
 7 

 VOLUNTARY TERMINATION OF EMPLOYMENT 

Should you resign from employment with Teva or should your Teva employment be terminated with cause during your assignment, Teva reserves the right to cease
all assignment payments, including payment of relocation costs, from the date of resignation or the date of misconduct, whichever is applicable. In a voluntary termination case, your signed payback agreement is enforced. 

PAYBACK AGREEMENT 
 As a condition of your assignment,
should you voluntarily terminate your assignment within 12 months of your effective assignment date, you are required to repay Teva a prorated sum towards relocation costs including: 

 

	 	•	 	 Household goods shipment 

 

	 	•	 	 Storage costs 

  

	 	•	 	 Temporary lodging (excluding associated per diem) 

 

	 	•	 	 Relocation allowance 

REPATRIATION BENEFITS 
 At the end of your assignment Teva
provides: 
  

	 	•	 	 Household goods move support with the same limitations as when you relocated to the Host Country

  

	 	•	 	 Flights back to the Home Country for you and your spouse/partner or dependents, and 

 

	 	•	 	 Thirty days temporary accommodations in accordance with the Teva global travel policy. 

 

	 	•	 	 Departure services: accommodation lease and utilities cancellation, visa cancellation, deregistration with local
authorities, and the closing of bank account. 

 Teva’s dedicated relocation provider will assist and all fees will be paid directly.

 LOCALIZATION 
 If at any time during or at the end of
your assignment, the Business decides that you are needed in the host country for an indefinitely, your assignment will not be extended. Instead, with your agreement, you will be localized in accordance with Teva global mobility policy in force at
the time of localization. This means that your employment with your Home country will end and you will become an employee of the Host country on Host country terms and your assignment related allowances will stop. As part of your localization, Teva
will work to transition you and your spouse/family to an immigration status that would allow you to remain in the Host country. 
 EMPLOYMENT TERMINATION

 In case of employment termination, the notice period should be according to your local employment agreement with Teva Pharmaceuticals Europe BV as
follows: The employment agreement may be terminated by either party as per last of a calendar month, by giving notice to the other party. Employee shall in that respect observe a notice period of 3 months and Teva Europe shall in that respect
observe a notice period of 6 months. During this period, Employee is prohibited to directly or indirectly engage in any activities for any other company competing in any way with Teva Europe or an affiliated company of the Teva-group, also in case
Teva Europe decides to put him on garden leave. 

  
 8 

 If a suitable work position is not available upon the expiration of the assignment period or in case this
assignment is terminated for reasons other than termination with cause, the above will also apply and severance will be according to the terms of the Home Company. 

We are very happy to offer you this opportunity for a Long Term International Assignment and feel your skills and accomplishments are an excellent match for
the challenges ahead. 
  

	
	 Sincerely,

	 Moshe Netzer

	 SVP Human Resources – Growth Markets Reg

	 /s/ Moshe Netzer

 I acknowledge that I had an assignment briefing with a Global Mobility representative, and I had the opportunity to ask
questions regarding the policy. I further understand my signature above indicates my acceptance of these terms and conditions. 
  

					
	 /s/ Gianfranco Nazzi
	  		  	 22.05.2017

	Gianfranco Nazzi	  		  	Date

  

	
	Cc:
	HRBP - Daniel Lawlor
	Host Manager - Dipankar Bhattacharjee
	Home HR – Moshe Netzer
	Host HR – Raffi Hirsh

  
 9EX-10.13

 Exhibit 10.13 

Execution Version 

EMPLOYMENT AGREEMENT 
 This
Employment Agreement (this “Agreement”) is entered on November 6, 2019, and is made by and between TEVA PHARMACEUTICAL INDUSTRIES LTD., an Israeli corporation located at 5 Basel Street, Petach Tikwa, Israel, Company No. 52-001395-4 (the “Company”, “Teva”), and Eli Kalif (“Executive”). 

WHEREAS, the Company wishes to employ Executive as its Chief Financial Officer (“CFO”), and Executive wishes to be so employed; and

 WHEREAS, the parties have agreed on the terms pursuant to which Executive shall serve as CFO, and wish to set forth such terms in this Agreement.

 NOW, THEREFORE, THE PARTIES HAVE AGREED AS FOLLOWS: 
  

	 	1.	 Term; Positions and Duties; Location 

 

	 	1.1	 The Company agrees to employ Executive, and Executive agrees to serve the Company and its affiliates, subject
to the terms and conditions of this Agreement, for the period commencing on December 22, 2019 (the “Effective Date”) and until the termination of this Agreement pursuant to Section 7 of this Agreement (the
“Term”). 

  

	 	1.2	 Executive shall report directly to the President and Chief Executive Officer of Teva (“CEO”).
Executive shall have all of the duties, authorities and responsibilities customarily exercised by an individual serving as the CFO of a company the size and nature of the Company. In addition, the Executive shall have such additional executive
duties and responsibilities as may be assigned to him by the CEO. 

  

	 	1.3	 The Executive shall devote his full business time, attention, and efforts to the performance of his duties
under this Agreement and shall not engage in any other business or occupation during the Term, including, without limitation, any activity that (a) conflicts with the interests of the Company or its affiliates, (b) interferes with the
proper and efficient performance of his duties for the Company or (c) interferes with the exercise of his judgment in the Company’s or its affiliates’ best interests. Notwithstanding the foregoing, nothing herein shall preclude the
Executive from: (i) serving, with the prior written consent of the CEO, as a member of the board of directors or advisory boards (or their equivalents in the case of a non-corporate entity) of non-competing businesses and charitable organizations; (ii) engaging in charitable activities and community affairs; (iii) speaking at meetings of business, charitable and civic organizations; or
(iv) managing his personal investments and affairs; provided, however, that the activities set out in clauses (i), (ii), (iii) and (iv) shall be limited by the Executive so as not to be in contradiction to any Company policy and/or
materially interfere, individually or in the aggregate, with the performance of his duties and responsibilities hereunder or create a potential business or fiduciary conflict. 

	 	1.4	 During the Term, and as part of Executive’s position, Executive may be required to serve as a director,
officer or committee member of the Company and its subsidiaries and affiliates (collectively, the “Company Group”), and the fulfillment of such position shall not constitute an employer-employee relationship between Executive and
any such entity (other than the Company), and notwithstanding any such position, Executive shall only be considered to be an employee of the Company and shall not be entitled to receive any additional compensation for serving in such additional
position. 

  

	 	1.5	 Executive’s principal place of employment shall be at the Company’s principal offices in Israel.
However, Executive acknowledges and agrees that he shall be required to travel abroad extensively on Company business. 

  

	 	1.6	 Executive acknowledges and agrees that no collective and/or special bargaining agreement that might apply to
the Company’s employees shall apply to Executive in his capacity as an employee of the Company, unless required by applicable Law. 

  

	 	1.7	 This Agreement and all compensation and benefits payable hereunder are subject to the Company’s
compensation plans and policies applicable to senior officers or any successor compensation plans or policies, including the Company’s Compensation Policy for Executive Officers and Directors adopted by the shareholders at the 2019 annual
general meeting of shareholders (the “Compensation Policy”) and nothing herein shall derogate in any way from the Company’s rights thereunder. 

 

	 	2.	 Base Salary 

  

	 	2.1	 The Executive’s gross annual base salary shall be 2,343,200 New Israeli Shekels (the “Annual
Salary”). The Annual Salary shall be divided by 12, and each such 1/12 shall constitute Executive’s monthly salary (the “Monthly Salary”) payable in arrears in monthly installments. The Annual Salary shall be reviewed,
from time to time, by the Human Resources & Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) and/or the Board of Directors. 

 

	 	2.2	 Executive hereby acknowledges and agrees that in light of his position and areas of responsibility, which
require a special degree of trust, and since he is part of the Company’s senior management, the provisions of the Hours of Work and Rest Law, 5711-1951, shall not apply to his employment. 

 

	 	2.3	 It is hereby agreed that only the Monthly Salary payable to Executive pursuant to Section 2.1 shall
constitute the basis for the calculation of all social benefits granted to Executive pursuant to this Agreement (including contributions and deductions related to the Insurance Arrangements (as such term is defined below)) and for any other purpose
or benefit plan for which deductions are calculated based on a percentage of Executive’s salary. 

  
 2 

	 	2.4	 The parties hereby acknowledge and agree that the compensation terms set forth in this Agreement constitute
fair consideration to Executive, given, inter alia, his managerial responsibilities and obligations towards the Company and that the Executive shall not be entitled to receive any other payment or compensation of any kind beyond the Monthly Salary
and the other payments and benefits specified in this Agreement unless otherwise agreed between the Company and the Executive in writing and approved as required by applicable Law. 

 

	 	2.5	 The Company shall pay or reimburse Executive for all reasonable out-of-pocket business expenses incurred by Executive in performing his duties under this Agreement, subject to presentation of appropriate supporting documentation and in accordance with the expense
reimbursement policy of the Company. 

  

	 	3.	 Annual Bonus 

  

	 	3.1	 For each fiscal year that ends during the Term, the Executive shall be eligible to be considered for an annual
bonus under the Company’s annual cash bonus plan in accordance with the Compensation Policy (the “Annual Bonus”) and subject to the sole discretion of the CEO, the Compensation Committee and the Board of Directors, with a
target amount equal to 100% of Executive’s Annual Salary. If payable, the Annual Bonus shall be paid to the Executive at the same time as annual bonuses are generally payable to other similarly situated senior executives of the Company, subject
to the Executive’s continuous employment through the payment date. For the avoidance of doubt, Executive shall not be eligible to be considered for Annul Bonus for 2019. 

 

	 	4.	 Equity Awards 

 

	 	4.1	 Sign-On Equity-based Award. Executive shall be granted a one-time award of Restrictive Share Units (“Sign-On RSU”) in a total fair market value of U.S. $250,000 at Grant Date, subject to (i) the Executive’s
commencement of employment with the Company, (ii) the terms of TPI’s 2015 Long Term Equity-Based Incentive Plan (the “2015 Plan”) (including any applicable sub-plans and the terms of
the award agreement), (iii) the Executive’s acceptance of the award agreement (iv) the Compensation Policy, and (v) any applicable law. The number of RSUs shall be determined according to the fair value of RSU on or about the
Grant Date (as defined below), in accordance with the terms of the 2015 Plan and the resolutions of the Compensation Committee and the Board, and based on Company practice. The Sign-on RSU shall vest in equal
installments on the second (2nd), third (3rd) and fourth (4th) anniversaries of the Grant Date. The Sign-On RSU will be granted on the Effective Date (or, if the Company is subject to a blackout on the
Effective Date, the first day of trading after the blackout period ends) (the “Grant Date”). 

  
 3 

	 	4.2	 Annual Equity-based Awards. During the Term, the Executive shall be considered for equity-based
compensation awards under the Equity Plan or any successor equity compensation plan(s), at the sole discretion of the CEO, the Compensation Committee and the Board of Directors. Any such awards shall be granted on such terms and conditions as may be
determined by the Compensation Committee and the Board of Directors. 

  

	 	5.	 Executive Benefits 

 

	 	5.1	 During the Term, Executive (and, to the extent eligible, his dependents and Beneficiaries (as defined below))
shall be entitled to participate in any and all health, medical, dental, group insurance (including life insurance), welfare, fringe benefits, perquisites and other employee benefit plans, programs and arrangements that are generally available from
time to time to similarly situated senior executives of the Company and their dependents and Beneficiaries (the “Executive Benefits”). Nothing contained herein shall be construed to limit the Company’s ability to amend,
suspend, or terminate any employee benefit plan or policy at any time without providing the Executive notice, and the right to do so is expressly reserved. 

  

	 	5.2	 Vacation. Executive shall be entitled to twenty three and a half (23.5) paid vacation working days per
calendar year during the Term, which shall accrue in accordance with Company policy. Executive shall be required to utilize at least five (5) consecutive vacation days every calendar year, and may accumulate the remaining vacation days up to 47
days in total and in accordance with Company policy which may be revised from time to time. Any accumulated vacation days above 47 days shall be forfeited by the Company with no consideration. The dates of Executive’s annual vacation shall be
coordinated in advance with the CEO. 

  

	 	5.3	 Sick Leave. Executive shall be entitled to twenty two (22) paid sick working days per calendar year
during the Term (without any reduction in the compensation or benefits payable hereunder), which may accumulate during the Term in accordance with the Company’s practice or policy, as in effect from time to time but in no event shall exceed
twelve (12) months. The sick pay shall include the Monthly Salary and all other amounts and benefits to which Executive is entitled under this Agreement, as if Executive worked at the Company during the period of his illness (in respect of
period for which he is entitled to receive payment as aforesaid), less any amount that Executive is entitled to receive with respect to the aforementioned period of his illness, including from any Israeli pension fund; provided that Executive
provides the Company with medical confirmation of his illness. The parties hereto hereby acknowledge and agree that the payments to Executive set forth in this Section 5.3 and Executive’s insurance in the pension fund and/or loss of
ability to work are meant to also cover the Company’s obligations under the Sick Pay Law, 57361976. 

  
 4 

	 	5.4	 Recreation Pay. Executive shall be entitled to fifteen (15) paid recreation days per calendar year
during the Term (without any reduction in the compensation or benefits payable hereunder). The amount of recreation pay per recreation day, the payment conditions and any other conditions governing recreation pay shall be in accordance with
applicable Law and the Company’s policy in effect at the applicable time with respect to its employees generally. 

  

	 	5.5	 Study Fund. For every month in which the Executive is employed, Teva shall make contributions on
Executive’s behalf to a study fund (keren hishtalmut) (the “Study Fund”), in an amount equal to 7.5% (seven and one half percent) of the Monthly Salary in such month, and shall deduct 2.5% (two and one half percent) from the
Monthly Salary, and transfer these amounts to the Study Fund. By signing this Agreement, the Executive hereby irrevocably grants Teva a power-of attorney to exercise the aforementioned deduction from the
Executive’s Monthly Salary. 

  

	 	5.6	 Car. The Company shall furnish the Executive with a car owned or leased by Teva, and which the Executive
shall use during the Term. Subject to the provisions of any applicable Law, and the Company’s policy on the matter, the Company shall bear all costs relating to the use and maintenance of the car. The Executive undertakes to use the car in a
reasonable manner. 

  

	 	6.	 Pension, Severance and Remuneration 

 

	 	6.1	 It is hereby declared and agreed that the rights of the Executive to pension allowance (kitzba), severance
payment and remuneration will be insured in a pension fund, managers’ insurance, provident fund and/or any combination of the foregoing, according to the Executive’s choice, as set forth herein below. 

 

	 	6.2	 The Executive will specify, in a notice to Teva, which part of the Monthly Salary shall be insured in each of
the programs specified below (the “Insurance Arrangement”). To the extent the Executive does not notify the Company of his choice, the Executive’s Monthly Salary shall be insured in accordance with the Company’s
policy. For the avoidance of doubt, it is hereby clarified that the accumulated contributions according to the Insurance Arrangement shall not be made, in any event, from an amount exceeding the Monthly Salary. 

  
 5 

	 	6.3	 The rate of allocations to the pension fund and/or managers’ insurance and/or provident fund, subject to
the Insurance Arrangement, shall be as follows: 

  

	 	6.3.1	 Remunerations – The Company shall contribute 7.5% out of the Monthly Salary according to the Insurance
Arrangement to the remuneration component, and deduct the Executive’s contribution in the rate of 6% out of the Monthly Salary according to the Insurance Arrangement for this purpose. 

It is hereby clarified that the Company’s contributions to the remuneration component to managers’ insurance and/or provident fund,
shall include a contribution of 5% for the remuneration component as well as payment for acquiring loss of ability to work insurance to insure 75% of the Monthly Salary according to the Insurance Arrangement. For the avoidance of any doubt, it is
hereby clarified that (i) the Company’s contributions percentages to the remuneration component for managers’ insurance and/or provident fund shall not be lower than 5% of the Monthly Salary, and (ii) the total amount of the
Company’s contributions, including loss of ability to work insurance shall not be higher than 7.5% of the Monthly Salary and (iii) in the event that the cost of the loss of ability to work insurance shall be lower than 2.5% of the Monthly
Salary according to the Insurance Arrangement, the remainder shall be contributed to the remuneration component for the benefit of the Executive, as detailed above. 
  

	 	6.3.2	 Severance Pay – The Company shall contribute each month an amount equal to 8.33% of the Monthly Salary to
the component of Severance Pay (the “Severance Contribution”). 

  

	 	6.4	 In the event of an increase in the Executive’s Monthly Salary, the Executive shall be entitled to choose
(in accordance with the Provident Funds Articles of Association and applicable provisions of Law) the Insurance Arrangement which will apply to the increase in the Monthly Salary. The Executive shall notify the Company with respect to such choice in
accordance with the Company’s policies regarding this matter. The provisions of Section 6.3 above shall apply to the Insurance Arrangement, which the Executive chose for the increase in the Monthly Salary. 

It is hereby declared and agreed that in the event of an increase in the Executive’s Monthly Salary, the Company shall not have an
obligation to contribute to the pension fund and/or managers’ insurance and/or the provident funds its indebtedness for severance payment, which derives (if at all) from the aforementioned increase, with respect to the term of employment prior
to the salary increase. 
  

	 	6.5	 By signing this Agreement, the Executive grants the Company an irrevocable power of attorney to deduct from his
salary the contributions relating to the Monthly Salary, and to transfer such amounts to any of the pension fund and/or managers’ insurance and/or the provident funds included in the Insurance Arrangement, which he chose, all as set forth in
Section Error! Reference source not found. above. 

  
 6 

	 	7.	 Termination of Employment 

 

	 	7.1	 General. Executive’s employment with the Company shall terminate upon the earliest to occur of
(a) Executive’s death, (b) a termination by reason of a Disability, (c) a termination by the Company with or without Cause, and (d) a termination by Executive with or without Good Reason. The date on which
employee-employer relations cease to exist between the parties shall be referred to in this Agreement as the “Date of Termination.” Upon any termination of Executive’s employment for any reason, except as may otherwise be
requested by the Company in writing and agreed upon in writing by Executive, Executive shall be deemed to have resigned, effective immediately, from any and all directorships, committee memberships, and any other positions Executive holds with any
member of the Company Group. If for any reason this Section 7.1 is deemed to be insufficient to effectuate the resignations contemplated by the immediately preceding sentence, then Executive shall without incurring any costs on him, upon the
Company’s request, execute any documents or instruments that the Company may deem necessary or desirable to effectuate such resignations. In addition, Executive hereby designates the Secretary or any Assistant Secretary of the Company to
execute any such documents or instruments as Executive’s attorney-in-fact to effectuate such resignations if execution by the Secretary or any Assistant Secretary
of the Company is deemed by the Company to be a more expedient means to effectuate such resignation or resignations. In addition, Executive undertakes to cooperate with the Company to ensure the orderly transition of position and provide any other
assistance that may be required by the Company in connection with the Executive’s duties and responsibilities. 

Furthermore, upon any termination of Executive’s employment for any reason, except for termination for Cause, the Company shall provide
Executive with letters addressed to the pension fund, managers insurance, provident fund and Study Fund (as applicable) that will enable Executive to receive any amounts due to him in connection with the termination of his employment. 

 

	 	7.2	 Termination Due to Death or Disability. Executive’s employment shall terminate automatically upon
his death. The Company may terminate Executive’s employment immediately upon the occurrence of a Disability (as defined in Section 8.4), such termination to be effective upon Executive’s receipt of written notice of such termination
and subject to applicable proceedings pursuant to applicable Law. Upon Executive’s death or in the event that Executive’s employment is terminated due to his Disability, Executive or his estate or his Beneficiaries, as the case may be,
shall be entitled to: 

  

	 	7.2.1	 The Accrued Obligations; 

 

	 	7.2.2	 Amounts accumulated in the funds pursuant to the Severance Contributions; 

  
 7 

 Notwithstanding the foregoing provisions of this Section 7.2, the payments and
benefits described in this Section 7.2 (other than the components of the Accrued Obligations and any portion of the Severance Payment required to be paid pursuant to applicable Law) (a) are subject to Executive’s or his estate or his
Beneficiaries, as the case may be, execution and non-revocation of the Release of Claims in accordance with Section 7.6 and (b) shall immediately terminate, and the Company shall have no further
obligations to Executive with respect thereto, in the event that Executive breaches any provision of Sections Sections 9, 10, 11, 12 or 13. In addition, in the event Executive breaches any provision of Sections 9, 10, 11 12 or 13, Executive shall
repay to the Company all payments and benefits which were made and/or paid by the Company pursuant to Section 7.4 (other than the components of the Accrued Obligations and the portion of the Severance Payment required to be paid pursuant to
applicable Law) 
  

	 	7.3	 Termination by the Company for Cause. 

 

	 	7.3.1	 The Company may terminate Executive’s employment at any time and without any advance notice, in the event
of Cause. 

  

	 	7.3.2	 In the event that the Company terminates Executive’s employment for Cause, he shall be entitled only to
those components of the Accrued required to be paid by applicable Law, and subject to applicable Law. 

  

	 	7.3.3	 In the event of termination of employment for Cause, the Executive shall be entitled to receive from Teva
appropriate letters regarding his termination of employment with Teva, addressed to the pension fund, provident funds and/or the insurer of the managers’ insurance, pursuant to which the Executive shall be entitled to receive from them the
amounts accumulated therein in the Executive’s favor from the contributions of the parties to remuneration, together with linkage differentials and earnings on such contributions, and Teva shall be entitled to the amounts accumulated in such
funds that constitute the aggregate Severance Contributions. In the event that the Executive has reimbursed Teva an amount equal to the Severance Contributions, then the Executive shall be entitled to receive from Teva letters as specified in
Section 7.1 above without any reservations. In addition, the Executive shall be entitled to receive a letter addressed to the Study Fund according to which Executive will be entitled to receive only the amounts contributed by the Executive to
the Study Fund, and Teva shall be entitled to the employer contributions made by Teva to the Study Fund. 

  

	 	7.3.4	 Following such termination of Executive’s employment by the Company for Cause, except as set forth in this
Section 7.3, Executive shall have no further rights to any compensation or any benefits under this Agreement. 

  
 8 

	 	7.4	 Termination by the Company without Cause. The Company may terminate Executive’s employment at any
time without Cause, effective six (6) months following the date of Executive’s receipt of notice of such termination (the “Company Notice Period”); provided, however, that the Company may, in its sole
and absolute discretion and by written notice, waive the services of the Executive during the Company Notice Period or in respect of any part of such period, and at the Company’s sole discretion accelerate the effective date of such termination
of employee-employer relationship (such accelerated date shall constitute the Termination Date), all on the condition that the Company pay the Executive the Monthly Salary and all additional compensation and benefits to which the Executive is
entitled in respect of the Notice Period without regard to any such Company waiver. 

 In the event that Executive’s
employment is terminated by the Company without Cause (other than due to death or Disability), Executive shall be entitled to: 
  

	 	7.4.1	 The Accrued Obligations; 

 

	 	7.4.2	 The Severance Payment (as such term is defined below); and 

 

	 	7.4.3	 If Executive’s employment is terminated by the Company without Cause within one (1) year following a
Change In Control event (as defined in the Compensation Policy as in effect on the date hereof), the CIC Amount (as defined below). 

  

	 	7.4.4	 Notwithstanding the foregoing, the payments and benefits described in this Section 7.4 (other than the
components of the Accrued Obligations and the portion of the Severance Payment required to be paid pursuant to applicable Law) (a) are subject to Executive’s execution and non-revocation of the
Release of Claims in accordance with Section 7.7 and (b) shall immediately terminate, and the Company shall have no further obligations to Executive with respect thereto, in the event that Executive breaches any provision of Sections 9,
10, 11 12 or 13. In addition, in the event Executive breaches any provision of Sections 9, 10, 11 12 or 13, Executive shall repay to the Company all payments and benefits which were made and/or paid by the Company pursuant to Section 7.4 (other
than the components of the Accrued Obligations and the portion of the Severance Payment required to be paid pursuant to applicable Law) 

  

	 	7.5	 Termination by Executive with or without Good Reason. Executive may terminate his employment with or
without Good Reason by providing the Company six (6) months’ prior written notice of such termination (the “Executive Notice Period”); provided, however, that the Company may, in

  
 9 

	 	
its sole and absolute discretion, by written notice, waive the services of the Executive during the Executive Notice Period or in respect of any part of such period, and at Company’s sole
discretion accelerate the effective date of such termination of employee-employer relationship (such accelerated date shall constitute the Termination Date) and still have it treated as a termination without Good Reason. 

In the event of a termination of employment by Executive for Good Reason, Executive shall be entitled to the same payments and benefits as
provided in Sections 7.4.1 and 7.4.2, subject to the same conditions on payment and benefits as described in Section 7.4 (including execution and non-revocation of the Release of Claims in accordance with
Section 7.6 and compliance with Sections 9, 10, 11, 12 or 13). Notwithstanding the above, the Company may terminate the employment of Executive without Cause in accordance with Section 7.1 after receipt of the “Good Reason
Notice” (as defined below). 
 In the event of a termination of employment by Executive without Good Reason, Executive shall be
entitled to only the Accrued Obligations and the Severance Contributions accumulated in the Insurance Arrangements; 
  

	 	7.6	 Release. Notwithstanding any provision in this Agreement to the contrary, the payment of any amount or
provision of any benefit pursuant to Section 7 (other than the components of the Accrued Obligations and those components of the Severance Payment required to be paid pursuant to applicable Law) (collectively, the “Severance
Benefits”) shall be conditioned upon Executive’s execution, delivery to the Company, and non-revocation of the Release of Claims within thirty (30) days following the Date of Termination. If
Executive fails to execute the Release of Claims in such a timely manner or revokes the Release of Claims, Executive shall not be entitled to any of the Severance Benefits. For the avoidance of doubt, in the event of a termination due to
Executive’s death or Disability or Executive’s death or Disability following a notice of termination of employment without Cause or for Good Reason, Executive’s obligations herein to execute and not revoke the Release of Claims may be
satisfied on his behalf by his estate or a person having legal power of attorney over his affairs. 

  

	 	7.7	 Full Settlement. The payments and benefits provided under this Section 7 shall be in full
satisfaction of all obligations of the Company Group to Executive under this Agreement or any other agreement, plan, arrangement or policy of the Company Group in connection with his termination of employment. For the avoidance of doubt,
Executive’s sole and exclusive remedy upon a termination of employment shall be receipt of the payments and benefits specified in this Section 7. 

  

	 	7.8	 Definitions. For purposes of this Agreement, the following terms have the following meanings:

  
 10 

	 	7.8.1	 “Accrued Obligations” means (a) any unpaid Monthly Salary earned through the Date of
Termination, and any unused vacation days and recreation days accrued in accordance with Company policy and this Agreement through the Date of Termination, which amounts shall be paid on the next regular payroll date immediately following the Date
of Termination, (b) any other payment to which Executive is entitled under the applicable terms of any applicable plan, program, agreement, corporate governance document or arrangement of the Company or its affiliates, including Company
reimbursement of any unreimbursed business expenses and rights to any Company indemnification as set forth in Section 8. 

  

	 	7.8.2	 “Beneficiaries” means, subject to applicable Law, the executors of Executive’s estate,
the Executive’s legal heirs and those beneficiaries whom the Executive stipulated in a written notice to any applicable Insurance Arrangement Providers. 

  

	 	7.8.3	 “Cause” means (A) the Executive’s indictment for, conviction of or pleading of
guilty or nolo contendere to, (i) a felony or (ii) any crime involving moral turpitude; (B) the Executive’s embezzlement, dishonesty, misappropriation of Company property, breach of fiduciary duty or fraud with regard to the
Company or any of its assets or businesses; (C) the Executive’s willful misconduct or gross negligence in the performance of the Executive’s duties or continual failure to perform the material duties of his position; (D) the
Executive’s material violation of a Company rule or regulation; (E) the Executive’s breach of a material provision of this Agreement; or (F) circumstances entitling the Company under any applicable law to terminate the employment
of the Executive without payment of severance pay. 

  

	 	7.8.4	 “Disability” means that Executive, due to a physical or mental disability, has been
substantially unable to perform his duties under this Agreement for a continuous period of ninety (90) days or longer, as determined by a physician selected by the Company and reasonably acceptable to Executive. 

 

	 	7.8.5	 “Good Reason” means a termination by Executive if (a) any of the following events occurs
without Executive’s express prior written consent, (b) Executive notifies the Company in writing that such event has occurred, describing such event in reasonable detail and demanding cure, within ninety (90) days after Executive
learns of the occurrence of such event (the “Good Reason Notice”), (c) such event is not substantially cured within thirty (30) days after Executive delivers the Good Reason Notice to the Company, and (d) the Date of
Termination occurs within one hundred twenty (120) days after the failure of the Company to so cure: (A) the Company’s breach of a material provision of this Agreement, (B) a material diminution in the Executive’s duties or
responsibilities that is inconsistent with the Executive’s position as described herein, or (C) a material reduction in the Executive’s rate of Annual Salary. 

  
 11 

	 	7.8.6	 “Law” means any Israeli law, rule or regulation, and the regulations of any securities
exchange on which the Company’s securities are listed, or any applicable judgment, order, writ, decree, permit or license of any governmental authority. 

  

	 	7.8.7	 “CIC Amount” means one and a half (1.5) million USD converted into local currency at the Date
of Termination and in accordance with the Company’s practice and polices. 

  

	 	7.8.8	 “Release of Claims” means the release of claims in favor of the Company and its affiliates
substantially in the form attached hereto as Exhibit A. 

  

	 	7.8.9	 “Severance Payment” means an amount equal to twice the most recent Monthly Salary
multiplied by the number of years of employment by Teva (pro rated for partial year) of which any amounts accumulated in the Insurance Arrangement as a result of the Severance Contributions shall be deducted, provided, however, that (i) in no
event shall the Executive (or, if applicable, his Beneficiaries) be entitled to receive from the Company an amount which, together with the Severance Contributions accumulated in the Insurance Arrangements, exceeds eighteen (18) months of the
Executive’s most recent Monthly Salary (unless required otherwise by applicable Law). 

  

	 	8.	 Indemnification 

 

	 	8.1	 In accordance with and subject to the provisions of applicable Law and the applicable provisions of the
Company’s Articles of Association and the Compensation Policy then in effect, Executive shall be indemnified and released by the Company in accordance with the provisions of the Indemnification and Release Agreement attached hereto as
Exhibit B, the terms of which shall be incorporated by reference herein. 

  

	 	9.	 Confidentiality and Disclosure of Information 

Executive shall execute the Confidentiality, Disclosure of Information and Assignment of Inventions Agreement attached hereto as Exhibit
C concurrently with the execution of this Agreement and agrees to abide by the terms thereof, which shall be deemed incorporated into this Section 9. 
  

	 	10.	 Non-Competition 

By signing this Agreement, the Executive hereby acknowledges and agrees that, in his capacity as Executive Vice President, Chief Financial
Officer, the Executive will have a great deal of exposure and access to a broad variety of commercially valuable proprietary information of the Company Group, including, by way of illustration, confidential

  
 12 

 
information regarding the Company Group’s current and future products and strategies, costs and other financial information, R&D and marketing plans and strategies, etc. As a result of
the Executive’s knowledge of the above information and in consideration for the benefits offered by the Company under this Agreement, the Executive affirms and recognizes his continuing obligations with respect to the use and disclosure of
confidential and proprietary information of the Company Group pursuant to the Company Group’s policies and the terms and conditions of this Agreement, and hereby agrees that, during the Term and for the six (6) months following the Date of
Termination, the Executive shall not, directly or indirectly (whether as an officer, director, owner, employee, partner, consultant or other direct or indirect service provider) engage, directly or indirectly, anywhere in the world, in any activity,
business or any other engagement in the pharmaceutical industry, which competes with the business of any member of the Company Group as of the Date of Termination (including any business that any member of the Company Group is actively planning to
enter as of the Date of Termination), except with the Company’s prior written approval. Notwithstanding anything to the contrary contained in this Section 10, the foregoing shall not prevent Executive from acquiring for his own personal
investment not more than 1% of the outstanding voting securities of any publicly-traded corporation. 
 It is hereby agreed and clarified
that, when determining the above non-competition undertaking, the parties took into account the entire consideration provided to Executive pursuant to this Agreement, which is being made in consideration,
inter alia, for such undertaking. 
  

	 	11.	 Non-Solicitation 

Executive herby agrees that during the Term and for the six (6) months following the Date of Termination, the Executive shall not,
directly or indirectly, (i) solicit or induce, or in any manner attempt to solicit or induce, any person employed by, or as agent of, the Company Group to terminate such person’s contract of employment or agency, as the case may be, with
the Company Group, or (ii) divert, or attempt to divert, any person, concern or entity from doing business with the Company Group, or attempt to induce any such person, concern or entity to cease being a customer or supplier of the Company
Group. 
 It is hereby agreed and clarified that, when determining the above non-solicitation
undertaking, the parties took into account the entire consideration provided to Executive pursuant to this Agreement, which is being made in consideration, inter alia, for such undertaking. 

 

	 	12.	 No Disparagement 

During the Term and at all times thereafter, the Executive agrees not to (i) make any disparaging or defamatory comments regarding any
member of the Company Group or any of its current or former directors, officers, employees or products or (ii) make any negative or disparaging comments concerning any aspect of the Executive’s relationship with any member of the Teva
Group or any conduct or events relating to any termination of the Executive’s employment with the Company. 

  
 13 

 Nothing herein shall prevent Executive from testifying truthfully in any legal proceeding,
to any governmental or regulatory body or as may otherwise be required by applicable Law. 
 It is hereby agreed and clarified that, when
determining the above non-disparagement undertaking, the parties took into account the entire consideration provided to Executive pursuant to this Agreement, which is being made in consideration, inter
alia, for such undertaking. 
  

	 	13.	 Cooperation. 

During the Term and at all times thereafter, Executive agrees to cooperate with the Company and its attorneys in connection with any matter
related to the period he was employed by the Company and/or his services to any other member of the Company Group, including but not limited to any threatened, pending, and/or subsequent litigation, government investigation, or other formal inquiry
against any member of the Company Group, and shall make himself available upon reasonable notice to prepare for and appear at deposition, hearing, arbitration, mediation, or trial in connection with any such matters. Such cooperation will include
willingness to be interviewed by representatives of the Company and to participate in legal proceedings by deposition or testimony. To the extent reasonably practicable, the Company shall coordinate with Executive to minimize scheduling conflicts
with Executive’s business and personal commitments. The Company shall reimburse Executive for any reasonable re approved out-of-pocket expenses (including travel
expenses) incurred in connection with providing such assistance and subject to any terms and limitation in the Indemnification and Release Agreement 
  

	 	14.	 No-Hedging Policy;
No-Pledging Policy; Stock Ownership Guidelines. 

 Executive acknowledges and
agrees to adhere to the Company’s No-Hedging Policy, No-Pledging Policy and Stock Ownership Guidelines applicable to executive officers of the Company, as each may
be amended from time to time in the Company’s sole discretion 
  

	 	15.	 Return of Car, Equipment and Documents 

As of no later than the Date of Termination, or earlier than that if required by the Company, Executive shall return to the Company the car,
cell phone (or other hand-held device), laptop, credit card(s) and any other company equipment, if any, provided to Executive, and any other confidential or proprietary information of the Company that remains in Executive’s possession;
provided, however, that nothing in this Agreement or elsewhere shall prevent Executive from retaining and utilizing documents relating to his personal benefits, personal contact list, and the like; and such other records and documents
as may reasonably be approved by the CEO (such approval not to be unreasonably withheld or delayed). Executive shall confirm such return in writing to the Company promptly upon Company’s written request, together with confirmation that
Executive no longer has any Company property or confidential or proprietary information of the Company in his possession or control. 

  
 14 

	 	16.	 Assignability; Binding Nature 

This Agreement shall inure to the benefit of, and be binding on, the parties and each of their respective successors, heirs (in
Executive’s case) and assigns. No rights or obligations of the Company under this Agreement may be assigned or transferred by the Company except that such rights and obligations may be assigned or transferred pursuant to a merger or
consolidation, or the sale or liquidation of all or substantially all of the business and assets of the Company; provided that the assignee or transferee is the successor to all or substantially all of the business and assets of the Company
and such assignee or transferee contractually assumes the liabilities, obligations and duties of the Company, as contained in this Agreement. 
  

	 	17.	 Tax Payments; Clawback 

 

	 	17.1	 Tax and Social Security Payments. Executive hereby acknowledges and agrees that the payments and
benefits granted to him under this Agreement shall be subject to income tax deductions and other mandatory tax deductions which the Company is required to deduct and/or withhold by applicable Law, and further represents that, except as specifically
set forth in this Agreement, nothing in this Agreement shall be construed as imposing on the Company the obligation to pay taxes or any other obligatory payment imposed on Executive due to any payment or benefit, except that the Company shall pay
taxes related to the use of car pursuant to Section 5.6. 

  

	 	17.2	 Clawback. All payments made pursuant to this Agreement are subject to the “clawback”
provisions in the Compensation Policy as may be amended from time to time. By signing this Agreement, Executive grants the Company a power of attorney to deduct from the Monthly Salary and/or any other payments due to Executive by the Company, any
amounts owed by him, in accordance with applicable Law and any Company clawback provisions in the Compensation Policy. 

  

	 	18.	 Representations 

Executive represents that (a) he has provided to the Company complete and accurate information regarding the terms of all contracts,
arrangements, agreements, policies or understandings applicable to Executive, with prior employers or otherwise, which include post-employment covenants including those relating to competition or solicitation of third parties and (b) he is not
subject to (or has been released from all restrictive covenants under) any contract, arrangement, agreement, policy or understanding that in any way impacts his ability to enter into or fully perform his obligations under this Agreement. Executive
and the Company each represent and warrant (i) that such party is not otherwise unable to enter into and fully perform such party’s obligations under this Agreement; and (ii) that, upon the execution and delivery of this Agreement by
both parties, this Agreement shall be such party’s valid and binding obligation, enforceable against such party in accordance with its terms, except to the extent that enforceability may be limited by applicable bankruptcy, insolvency or
similar laws affecting the enforcement of creditors’ rights generally, or otherwise as may be limited by applicable Laws. Notwithstanding any portion of this Agreement to the contrary, if any of Executive’s representations under this
Section 18 prove to be inaccurate, the Company may immediately declare this Agreement null and void and Executive’s employment with the Company shall terminate immediately without obligation of any sort by the Company, including pursuant
to any equity or other award previously issued to Executive. 

  
 15 

	 	19.	 Notices 

Any notice or other communication required or permitted to be delivered under this Agreement shall be (a) in writing; (b) delivered
personally, by email received by the intended receiver of such email, by facsimile, by courier service or by certified or registered mail, first class postage prepaid and return receipt requested; (c) deemed to have been received on the date of
delivery or, if so mailed, on the third business day after the mailing thereof; and (d) addressed as follows (or to such other address as the party entitled to notice shall hereafter designate in accordance with the terms hereof): 

If to the Company: to the Company’s headquarters, Attn: CEO; 

If to Executive: to the last address on file with the Company. 

Miscellaneous 
  

	 	19.1	 Entire Agreement. As of the Effective Date, this Agreement shall constitute the entire agreement between
the parties with respect to the subject matter hereof, and this Agreement (including the agreements attached hereto as Exhibits) shall supersede all prior representations, agreements and understandings (including any prior course of dealings), both
written and oral, between the parties with respect to the subject matter hereof. 

  

	 	19.2	 Amendment or Waiver. No provision in this Agreement may be amended unless such amendment is set forth in
writing that expressly refers to the provision of this Agreement that is being amended and that is signed by Executive and by an authorized officer of the Company. No waiver by either party of any breach of any condition or provision contained in
this Agreement shall be deemed a waiver of any similar or dissimilar condition or provision at the same or any prior or subsequent time. To be effective, any waiver must be set forth in a writing signed by the waiving party and must specifically
refer to the condition(s) or provision(s) of this Agreement being waived. 

  

	 	19.3	 Inconsistencies. Subject to applicable Law, in the event of any inconsistency between any provision of
this Agreement and any provision of any applicable plan, program, agreement, corporate governance document or arrangement of the Company or its affiliates, the provisions of this Agreement shall control unless Executive and the Company otherwise
agree in a writing that expressly refers to the provision of this Agreement whose control they are waiving. 

  

	 	19.4	 Headings; Construction. The headings of the sections and
sub-sections contained in this Agreement are for convenience only and shall not be deemed to control or affect the meaning or construction of any provision of this Agreement. For purposes of this Agreement,
the term “including” shall mean “including, without limitation.” 

  
 16 

	 	19.5	 Survivorship. The provisions of this Agreement that by their terms call for performance subsequent to
the termination of either Executive’s employment or this Agreement (including the terms of Sections 7 through 13 and Section 19) shall survive such termination in accordance with their applicable terms. 

 

	 	19.6	 Governing Law; Severability. This Agreement shall be governed by the laws of the State of Israel,
without regard to its conflict of laws rules. Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective and valid under Law but the invalidity or unenforceability of any
provision or portion of any provision of this Agreement in any jurisdiction shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of this Agreement, including that
provision or portion of any provision, in any other jurisdiction. In addition, should a court or arbitrator determine that any provision or portion of any provision of this Agreement, is not reasonable or valid, either in period of time,
geographical area, or otherwise, the parties agree that such provision should be interpreted and enforced to the maximum extent which such court or arbitrator deems reasonable or valid. 

 

	 	19.7	 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be
deemed an original, but all such counterparts shall together constitute one and the same instrument. Signatures delivered by facsimile shall be effective for all purposes. 

 

	 	19.8	 Board Approvals. Any reference made in this Agreement to an approval required of the Board or a
committee of the Board shall also include any approval of the Board or any committee of the Board as may be required by Law, the Compensation Policy or the Company’s corporate documents. 

— Signature page follows – 

  
 17 

 IN WITNESS WHEREOF, the parties have executed this Agreement in one or more
counterparts as of the Effective Date. 
  

			
	TEVA PHARMACEUTICAL INDUSTRIES LTD.

 
			
	
	 /s/ Mark Sabag

	By:	 	Mark Sabag
	Title:	 	Chief HR Officer
	
	 /s/ Kåre Schultz

	By:	 	Kåre Schultz
	Title:	 	President & CEO

 
			
	
	EXECUTIVE
	
	 /s/ Eli Kalif

	Name:	 	Eli Kalif
	Dated:	 	

 [Signature Page to Employment Agreement] 

 Exhibit A 

Form of Release Agreement 
 This Release
Agreement (this “Release Agreement”) is dated as of [_____________] and is entered into by Eli Kalif (“Executive”, “Me” or “I”) and TEVA PHARMACEUTICAL INDUSTRIES LTD. (the
“Company”) in connection with the termination of Executive’s employment with the Company. 
 1. General Release. 

(a) In consideration for the receipt of those payments that are in excess of the amounts required to be paid to Me by Law (as detailed in the
settlement of account attached hereto), I, on behalf of myself and my family, agents, representatives, heirs, executors, trustees, administrators, attorneys, successors and assigns (the “Releasors”), hereby irrevocably and
unconditionally (i) represent and warrant that I have received in a timely manner full and complete payment of all amounts due to Me under my employment agreement with the Company or under any applicable law and/or in connection with the
termination of my employment, both at law and pursuant to the terms of the employment agreement, and (ii) release, settle, cancel, acquit, discharge and acknowledge to be fully satisfied, and covenant not to sue the Company and each of its
respective past and/or present subsidiaries, affiliates, successors and assigns, and each of their respective predecessors, and past and/or present stockholders, partners, members, directors, managers, officers, employees, agents or other
representatives, and employee benefit plans of the Company or its affiliates, including, but not limited to, trustees and administrators of these plans, in each case, in their individual and/or representative capacities (collectively, the
“Releasees”) from any and all claims, contractual or otherwise, demands, costs, rights, causes of action, charges, debts, liens, promises, obligations, complaints, losses, damages and all liability of whatever kind and nature,
whether known or unknown, and hereby waive any and all rights that I, he, she or it may have, from the beginning of time up to and including the time of signing this Release Agreement, in respect of my employment or separation from employment with
the Company, or is in any way connected with or related to any applicable compensatory or benefit plan, program, policy or arrangement, including, but not limited to, any claims relating to salaries, benefits, bonuses, compensation, fringe benefits,
social benefits according to any law or agreement, amounts of pension fund, overtime, severance pay, sick pay, recreation payments, vacation payments, prior notice payments, options or other securities, reimbursement of expenses and/or any other
payments or benefits due to Me by any of the Releasees, or claims under any policy, agreement, understanding or promise, written or oral, formal or informal, between the Company and any of its affiliates and myself, now or hereafter recognized,
including claims for wrongful discharge, slander and defamation, as well as all claims for counsel fees and costs; provided that such released claims shall not include any claims to enforce my rights under, or with respect to, any
post-termination obligations of the Company expressly undertaken by the Company under my employment agreement with the Company (including vested accrued benefits and compensation under the Company’s employee benefit plans and arrangements as
set forth in Section 7 to the Employment Agreement), rights as a shareholder of the Company and rights to indemnification and liability insurance coverage. 

  
 A-1 

 (b) The Releasors agree not to bring any action, suit or proceeding whatsoever (including
the initiation of governmental proceedings or investigations of any type) against any of the Releasees hereto for any matter or circumstance concerning which the Releasors have released the Releasees under this Release Agreement. Further, the
Releasors agree not to encourage any other person or suggest to any other person that he, she or it institute any legal action against the Releasees, and I hereby declare, confirm and undertake that, if the Releasors or anyone else in their name
should deliver a claim as mentioned above, I shall reimburse the Releasees and anyone else on their behalf to the full extent of the sum of the legal expenses and legal fees incurred by them as a result of any such claim; and in the event that
Releasors prevail in such legal action, then the Releasees shall reimburse such sum to Me or the Releasors. The Releasors hereby agree to waive the right to any relief (monetary or otherwise) in any action, suit or proceeding I may bring in
violation of this Release Agreement. 
 (c) This Release Agreement shall constitute a dismissal and compromise notice for the purposes of
Section 29 of the Severance Pay Law 5713-1963. 
 2. Legal Advice, Reliance. I represent and acknowledge that (a) I have been given adequate
time to consider this Release Agreement and have been advised to discuss all aspects of this Release Agreement with my private attorney, (b) I have carefully read and fully understand all the provisions of this Release Agreement, (c) I
have voluntarily entered into this Release Agreement, without duress or coercion, and (d) I have not heretofore assigned or transferred or purported to assign or transfer, to any person or entity, any of the claims described in
Section 1(a), any portion thereof or any interest therein. I understand that if I request additional time to review the terms of this Release Agreement, a reasonable extension of time shall be granted. 

3. Miscellaneous. 
 (a) No Violation of
Law. I agree and acknowledge that this Release Agreement is not and shall not be construed to be an admission by the Company of any violation of any applicable laws of Israel, or of any duty owed by the Company to Me. 

(b) Governing Law; Severability. This Release Agreement shall be governed by the laws of the State of Israel, without regard to its
conflict of laws rules. In the event that any one or more of the provisions of this Release Agreement is held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be
affected or impaired thereby. 
 (c) Counterparts. This Release Agreement may be executed in one or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 *
        *         *         *         * 

 

	
	Very truly yours,
	
	EXECUTIVE
	
	
                    
    

	Name:
                                         
                                
	Dated:
                                         
                                

  
 A-2 

 
			
	ACCEPTED AND AGREED:
	
	TEVA PHARMACEUTICAL INDUSTRIES LTD
	
	         

	By:	 	
	Title:	 	
	
	         

	By:	 	
	Title:	 	

  
 A-3 

 Exhibit B 

Indemnification Agreement 

Indemnification and Release Agreement 

This Indemnification and Release Agreement (this “Indemnification Agreement”) is being entered into, pursuant to the
resolutions of the Board of Directors (the “Board”) of Teva Pharmaceutical Industries Ltd., a company organized under the laws of the State of Israel (the “Company”), dated July 31, 2012 and the resolutions of
the Human Resources and Compensation Committee of the Board, and the Audit Committee of the Board, each dated July 30, 2012. 
 It is
in the best interest of the Company to retain and attract as office holders the most capable persons available and such persons are becoming increasingly reluctant to serve in companies unless they are provided with adequate protection through
insurance, exemption and indemnification in connection with such service. 
 You are or have been appointed as an office holder of the
Company, and in order to enhance your service to the Company in an effective manner, the Company desires to provide for your indemnification to the fullest extent permitted by law and the Company’s Articles of Association (the “Articles
of Association”). In consideration of your service to the Company, the Company hereby agrees as follows: 
 1. The Company
hereby undertakes to indemnify you to the maximum extent permitted by the Articles of Association and the Israeli Companies Law, 5759 – 1999, as amended from time to time (the “Companies Law”), the Israeli Securities Law,
5728-1968, as amended from time to time (the “Securities Law”) and any other applicable law, in respect of the following expenses or liabilities imposed on, or incurred by, you in consequence of any act performed or omission
committed by you in your capacity as an “Office Holder” (such term shall bear the meaning assigned to it in the Companies Law) of the Company (including your service, at the request of the Company, as an officer, director, employee or
board observer of any other company controlled directly or indirectly by the Company (a “Subsidiary”) or in which the Company holds shares (an “Affiliate”)). 

1.1 any monetary liability imposed on you in favor of another person by a court judgment, including a settlement or an arbitrator’s
award which was approved by court; 
 1.2 reasonable litigation expenses, including attorneys’ fees, actually incurred by you in
connection with an investigation or proceeding that was conducted against you by a competent authority which has been Terminated Without the Filing of an Indictment (as such term is defined in the Companies Law) against you and without the
Imposition on you of a Monetary Liability In Lieu of a Criminal Proceeding (as such term is defined in the Companies Law), or which has been Terminated Without the Filing of an Indictment against you but with the Imposition on you of a
Monetary Liability in Lieu of a Criminal Proceeding in respect of a crime which does not require the proof of mens rea (criminal intent) or in connection with a monetary sanction; 

 1.3 reasonable litigation expenses, including attorneys’ fees, actually incurred
by you or charged to you by a court, in a proceeding instituted against you by the Company or on its behalf or by another person, or in any criminal proceeding in which you were acquitted, or in any criminal proceedings in which you were convicted
of a crime which does not require the proof of mens rea (criminal intent); and 
 1.4 payment which you are obligated to make
to an injured party as set forth in Section 52(54)(a)(1)(a) of the Securities Law, and expenses actually incurred by you in connection with a proceeding under Chapters H’3, H’4, or I’1 of the Securities Law, including reasonable
legal expenses, which term includes attorneys’ fees or in connection with Article D of Chapter Four of Part Nine of the Companies Law. 

For the purpose of this Indemnification Agreement, “expenses” shall include, without limitation, attorneys’ fees and all other
costs, expenses and obligations paid or incurred by you in connection with investigating, defending, being a witness in or participating in (including on appeal), or preparing to defend, be a witness in or participate in any claim relating to any
matter for which indemnification hereunder may be provided, and expenses paid or incurred by you in successfully enforcing this Indemnification Agreement. Expenses shall be considered paid or incurred by you at such time as you are required to pay
or incur such cost or expenses, including upon receipt of an invoice or payment demand. 
 2. Notwithstanding the forgoing provisions
of Section 1, except to the extent permitted by applicable law, the Company will not indemnify you for any amount you may be obligated to pay in respect of: 

2.1 A breach of your duty of loyalty to the Company or a Subsidiary or Affiliate, unless committed in good faith and with reasonable
grounds to believe that such act would not prejudice the interests of the Company or a Subsidiary or Affiliate; 
 2.2 A breach of
your duty of care to the Company or a Subsidiary or an Affiliate committed intentionally or recklessly; 
 2.3 An action or omission
taken by you with the intent of unlawfully realizing personal gain; 
 2.4 A fine, monetary sanction, forfeit or penalty imposed upon
you; or 
 2.5 With respect to proceedings or claims initiated or brought voluntarily by you against the Company or a Subsidiary or an
Affiliate, other than by way of defense, by way of third party notice to the Company or a Subsidiary or an Affiliate, or by way of countersuit in connection with claims brought against you. 

3. To the fullest extent permitted by law, the Company will, following receipt by the Company of your written request therefor, make
available all amounts payable to you in accordance with Section 1 above on the date on which such amounts are first payable by you (“Time of Indebtedness”), and with respect to items referred to in Sections 1.2, 1.3 and 1.4
above, even prior to the time on which the applicable court renders its decision, provided however, that advances given to cover legal expenses will be repaid by you to the Company if it is determined that you are not
lawfully entitled to such indemnification. 

  
 A-2 

 As part of the aforementioned undertaking, the Company will make available to you any
security or guarantee that you may be required to post in accordance with an interim decision given by a court or an arbitrator, including for the purpose of substituting liens imposed on your assets. 

4. The Company will indemnify you and advance expenses in accordance with this Indemnification Agreement even if at the relevant Time of
Indebtedness you are no longer an Office Holder of the Company or a Subsidiary or an Affiliate, provided that the obligations with respect to which you will be indemnified hereunder are in respect of actions taken or omissions
committed by you while you were an Office Holder of the Company or such Subsidiary or such Affiliate as aforesaid, and in such capacity. 

5. The undertaking of the Company set forth in Section 1.1 shall be limited as follows: 

5.1 to matters that are connected or otherwise related to those events or circumstances set forth in Schedule A hereto. 

5.2 the maximum amount for which the Company undertakes to indemnify you for the matters and circumstances described in Section 1.1,
jointly and in the aggregate, shall not exceed US$ 200 million according to the representative rate of exchange, or any other official rate of exchange that may replace it, at the Time of Indebtedness calculated with respect to each Office
Holder of the Company. Such amount has been determined by the Board to be reasonable under the circumstances. 
 6. Subject to the
limitations of Section 5 above and Section 7 below, the indemnification hereunder will, in each case, cover all sums of money that you will be obligated to pay, in those circumstances for which indemnification is permitted under the law,
the Articles of Association and under this Indemnification Agreement. 
 7. Notwithstanding anything to the contrary herein, the
Company will not indemnify you for any liability with respect to which you have received payment by virtue of an insurance policy or another indemnification agreement, including, without limitation, an indemnification undertaking provided by a
Subsidiary or an Affiliate, other than for amounts which are in excess of the amounts actually paid to you pursuant to any such insurance policy or other indemnity agreement (including deductible amounts not covered by insurance policies), all
within the limits set forth in Section 5 above. In order to eliminate any duplication of benefits, the Company will be entitled to receive any amount collected by you from a third party in connection with liabilities actually indemnified
hereunder, up to the amount actually paid to you by the Company as indemnification hereunder, to be transferred by you to the Company within fifteen (15) days following the receipt of the said amount. 

In the event of payment by the Company pursuant to this Indemnification Agreement, the Company shall be subrogated to the extent of such
payment to all of your rights of recovery, and you shall execute all documents required, and shall do everything that may be necessary, to secure such rights, including the execution of such documents necessary to enable the Company effectively to
bring suit to enforce such rights. 

  
 A-3 

 8. In all indemnifiable circumstances, indemnification will be subject to the
following: 
 8.1 You shall promptly notify the Company in writing of any legal proceedings initiated against you and of all possible
or threatened legal proceedings for which you may seek indemnification hereunder, without delay, and in any event within seven (7) days following your first becoming aware thereof, provided, however, that your
failure to notify the Company as aforesaid shall not derogate from your right to be indemnified as provided herein except and to the extent that such failure to provide notice prejudices the Company’s ability to defend against such action or to
conduct any related legal proceeding. You shall deliver to the Company, or to such person as it shall advise you, without delay all documents you receive in connection with these proceedings or possible or threatened proceedings. Notice to the
Company shall be directed to the Chairman of the Board, and in the event you are the Chairman of the Board, to the Chairman of the Audit Committee, at the address of the Company’s principal office (or at such other address as the Company shall
advise you). 
 8.2 Other than with respect to proceedings that have been initiated against you by the Company or in its name, the
Company shall be entitled to undertake the conduct of your defense in respect of such legal proceedings and/or to hand over the conduct thereof to any attorney which the Company may choose for that purpose, except to an attorney who is not, upon
reasonable grounds, acceptable to you. In such case, the fees and expenses of such counsel shall be paid by the Company. The Company shall notify you of any such decision to defend within ten (10) calendar days of receipt of notice of any such
proceeding. 
 The Company or the attorney as aforesaid shall be entitled, within the context of the conduct as aforesaid, to conclude such
proceedings, all as they shall see fit, including by way of settlement. 
 Notwithstanding the foregoing, in the case of criminal
proceedings, the Company or the attorneys as aforesaid will not have the right to plead guilty in your name or to agree to a plea-bargain in your name without your consent. Furthermore, in a civil proceeding (whether before a court or as a part of a
compromise arrangement), the Company and/or its attorneys will not have the right to admit to any occurrences that are not indemnifiable pursuant to this Indemnification Agreement and/or pursuant to law, without your consent. However, the aforesaid
will not prevent the Company or its attorneys as aforesaid, with the approval of the Company, to come to a financial arrangement with a plaintiff in a civil proceeding or to consent to the entry of any judgment against you or enter into any
settlement, arrangement or compromise, in each case without your consent, so long as such arrangement, judgment, settlement or compromise: (i) does not include an admission of your fault, (ii) is fully indemnifiable pursuant to this
Indemnification Agreement and pursuant to law and (iii) further provides, as an unconditional term thereof, the full release of you from all liability in respect of such proceeding. This paragraph shall not apply to a proceeding brought by you
under Section 8.7 below. 
 8.3 You will fully cooperate with the Company and/or any attorney as aforesaid in every reasonable
way as may be required of you within the context of their conduct of such legal proceedings, including but not limited to the execution of power(s) of attorney and other documents required to enable the Company or its attorney as aforesaid to
conduct your defense in your name, and to represent you in all matters connected therewith, in accordance with the aforesaid and will give the Company all information and access to documents, files and your advisors and representatives as shall be
within your power, in every reasonable way as may be required by the Company with respect to any such legal proceedings, provided that the Company shall cover all reasonable costs incidental thereto such that you will not be required to pay the same
or to finance the same yourself, and provided, further, that you shall not be required to take any action that would reasonably prejudice your defense in connection with any indemnifiable proceeding. 

  
 A-4 

 8.4 Notwithstanding the provisions of Sections 8.2 and 8.3 above, (i) if in
a proceeding to which you are a party by reason of your status as an Office Holder of the Company or any Subsidiary or Affiliate, the named parties to any such proceeding include both you and the Company or any Subsidiary or Affiliate, and joint
representation is inappropriate under applicable standards of professional conduct due to a conflict of interest or potential conflict of interest (including the availability to the Company and its Subsidiary or Affiliate, on the one hand, and you,
on the other hand, of different or inconsistent defenses or counterclaims) that exists between you and the Company, or (ii) if the Company fails to assume the defense of such proceeding in a timely manner, or (iii) if the Company refers
the conduct of your defense to an attorney who is not, upon reasonable grounds, acceptable to you, you shall be entitled to be represented by separate legal counsel, which may represent other persons similarly situated, of the Company’s choice
and reasonably acceptable to you and such other persons, at the sole expense of the Company. In addition, if the Company fails to comply with any of its material obligations under this Indemnification Agreement or in the event that the Company or
any other person takes any action to declare this Indemnification Agreement void or unenforceable, or institutes any action, suit or proceeding to deny or to recover from you the benefits intended to be provided to you hereunder, except with respect
to such actions, suits or proceedings brought by the Company that are resolved in favor of the Company, you shall have the right to retain counsel of your choice, reasonably acceptable to the Company and at the expense of the Company, to represent
you in connection with any such matter. 
 8.5 If, in accordance with Section 8.2 (but subject to Section 8.4), the Company
has taken upon itself the conduct of your defense, you shall have the right to employ counsel in any such action, suit or proceeding, who shall fully update, and be fully updated by, the Company on the defense procedure and shall consult with, and
be consulted with by, the Company and the attorney conducting the legal defense on behalf of the Company, but the fees and expenses of such counsel, incurred after the assumption by the Company of the defense thereof, shall be at your expense and
the Company will have no liability or obligation pursuant to this Indemnification Agreement or the above resolutions to indemnify you for any legal expenses, including any legal fees, that you may incur in connection with your defense, unless the
Company shall agree to such expenses; in which event all reasonable fees and expenses of your counsel shall be borne by the Company to the extent so agreed to by the Company. 

8.6 The Company will have no liability or obligation pursuant to this Indemnification Agreement to indemnify you for any amount expended
by you pursuant to any compromise or settlement agreement reached in any suit, demand or other proceeding as aforesaid without the Company’s consent to such compromise or settlement, which consent shall not be unreasonably withheld. 

8.7 The Board and/or applicable committee(s) thereof and/or any other person(s) authorized by the Board will consider the request for
indemnification and the amount thereof and will determine if you are entitled to indemnification and the amount thereof. In the event that you make a request for payment of an amount of indemnification hereunder or a request for an advancement of
indemnification expenses hereunder and the Company fails to timely determine your right to indemnification hereunder or fails to timely make such payment or advancement in 

  
 A-5 

 
whole or in part, you may request that a determination with respect to your entitlement thereto shall be made in the specific case by an Independent Counsel agreed upon by the Company and you,
and in the absence of such agreement, appointed by the head of the Israeli Bar Association. The Company agrees to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses,
claims, liabilities and damages arising out of or relating to this Indemnification Agreement or its engagement pursuant hereto, provided, however, that you shall reimburse the Company for any such fees, expenses, claims, liabilities and damages in
the event the matter is resolved in favor of the Company. “Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of Israeli corporate law and neither presently is, nor in the past five
years has been, retained to represent: (i) the Company, an “interested party” (as defined in the Companies Law) of the Company or you in any matter material to either such party (other than in the capacity of Independent Counsel with
respect to this Indemnification Agreement or similar indemnification agreements of the Company), or (ii) any other party to the proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term
“Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or you in an action to determine your
rights under this Indemnification Agreement. 
 8.8 Neither the Company nor any of its agents, employees, directors or officers shall
make any statement to the public or to any other person regarding any settlement of claims made pursuant to this Indemnification Agreement against you that would in any manner cast any negative light, inference or aspersion against you. 

8.9 By signing this Indemnification Agreement you hereby accept that you shall not make any statement to the public or to any other
person regarding any settlement of claims made pursuant to this Indemnification Agreement against you or the Company that would in any manner cast any negative light, inference or aspersion against the Company, and that you will keep the terms of
such settlement confidential. 
 9. The Company hereby exempts you, to the fullest extent permitted by law and the Articles of
Association, from any liability for damages caused as a result of a breach of your duty of care to the Company, provided that in no event shall you be exempt with respect to any actions listed in Section 2 above or for a breach of
your duty of care in connection with a Distribution (as defined in the Companies Law). 
 10. Subject to Section 20 below,
if any act, resolution, approval or other procedure is required for the validation of any of the undertakings in this Indemnification Agreement, the Company undertakes to cause them to be done or adopted in a manner which will enable the Company to
fulfill all its undertakings as aforesaid. 
 11. To the fullest extent permitted by law and the Articles of Association (as stated
above), nothing contained in this Indemnification Agreement shall derogate from the Company’s right (but in no way shall the Company be obligated) to indemnify you post factum for any amounts which you may be obligated to pay as set
forth in Section 1 above without regard to the limitations set forth in Section 5 above. Your rights of indemnification hereunder shall not be deemed exclusive of any other rights you may have under the Articles of Association or
applicable law or otherwise. 

  
 A-6 

 12. If any undertaking included in this Indemnification Agreement is held invalid or
unenforceable, such invalidity or unenforceability will not affect any of the other undertakings which will remain in full force and effect. Furthermore, if such invalid or unenforceable undertaking may be modified or amended so as to be valid and
enforceable as a matter of law, such undertaking will be deemed to have been modified or amended, and any competent court or arbitrator is hereby authorized to modify or amend such undertaking, so as to be valid and enforceable to the maximum extent
permitted by law. 
 13. This Indemnification Agreement and the agreements herein shall be governed by and construed and enforced in
accordance with the laws of the State of Israel, without regard to the rules of conflict of laws, and any dispute arising from or in connection with this Indemnification Agreement is hereby submitted to the sole and exclusive jurisdiction of the
competent courts in Tel Aviv, Israel. 
 14. This Indemnification Agreement cancels and replaces any preceding letter of
indemnification or arrangement for indemnification that may have been issued to you by the Company. Notwithstanding the foregoing, the indemnification obligation set forth in this Indemnification Agreement will also apply, subject to the terms,
conditions and limitations set forth in this Indemnification Agreement, with respect to actions performed, or omissions committed, in your capacity as an Office Holder of the Company or a Subsidiary or an Affiliate, during the period prior to the
date of this Indemnification Agreement. 
 15. Neither the settlement nor termination of any proceeding nor the failure of the Company
to award indemnification or to determine that indemnification is payable shall create an adverse presumption that you are not entitled to indemnification hereunder. In addition, the termination of any proceeding by judgment or order (unless such
judgment or order provides so specifically) or settlement shall not create a presumption that you did not act in good faith and in a manner which you reasonably believed to be in or not opposed to the best interests of the Company or, with respect
to any criminal action or proceeding, that you had reasonable cause to believe that your action was unlawful. 
 16. This
Indemnification Agreement shall be (a) binding upon all successors and assigns of the Company (including any transferee of all or a substantial portion of the business, stock and/or assets of the Company and any direct or indirect successor by
merger or consolidation or otherwise by operation of law), and (b) binding on and shall inure to the benefit of your heirs, personal representatives, executors and administrators. This Indemnification Agreement shall continue for your benefit
and your heirs’, personal representatives’, executors’ and administrators’ benefit after you cease to be an Office Holder of the Company. 

17. The obligations of the Company according to this Indemnification Agreement shall be interpreted broadly and in a manner that shall
facilitate its execution, to the extent permitted by law, and for the purposes for which it was intended. In the event of a conflict between any provision of this Indemnification Agreement and any provision of the law which cannot be conditioned
upon, changed or added to, the said provision of the law shall supersede the specific provision in this Indemnification Agreement, but shall not limit or diminish the validity of the remaining provisions of this Indemnification Agreement. 

  
 A-7 

 18. Subject to Section 20 below, the Company hereby agrees to indemnify and
exempt you to the fullest extent permitted by law, notwithstanding that such indemnification or exemption is not specifically authorized by the other provisions of this Indemnification Agreement. In the event of any change after the date of this
Indemnification Agreement in any applicable law, statute or rule which expands the right of an Israeli company to indemnify Office Holders, it is the intent of the parties hereto that you shall enjoy by this Indemnification Agreement the greater
benefits afforded by such change and such changes shall to the extent permitted by applicable law be, ipso facto, within the purview of your rights and the Company’s obligations pursuant to this Indemnification Agreement. 

19. Subject to Section 5 above and notwithstanding anything else to the contrary herein, in the event of any change in the Articles
of Association after the date of this Indemnification Agreement which narrows the Company’s right to indemnify you under this Agreement, such change shall apply only with respect to actions performed, or omissions committed, by you in your
capacity as an Office Holder of the Company, of a Subsidiary or of an Affiliate, after the date of such change, to the extent permitted by applicable law. 

20. Notwithstanding anything to the contrary herein, nothing in this Indemnification Agreement shall require or obligate the Company to
amend its Articles of Association, or take any action with respect thereto. 
 21. No waiver of any of the provisions of this
Indemnification Agreement shall be deemed or shall constitute a waiver of any other provisions of this Indemnification Agreement (whether or not similar), nor shall such waiver constitute a continuing waiver. Any waiver shall be in writing. 

22. All notices and other communications required or permitted under this Indemnification Agreement shall be in writing, shall be
effective (i) if mailed, three (3) business days after mailing (unless mailed abroad, in which case it shall be effective five (5) business days after mailing), (ii) if by air courier, two (2) business days after delivery to the
courier service, (iii) if sent by messenger, upon delivery, (iv) if sent via facsimile, upon transmission and electronic (or other) confirmation of receipt or (if transmitted and received on a
non-business day) on the first business day following transmission and electronic (or other) confirmation of receipt and (iv) if sent by email, on the date of transmission or (if transmitted and received
on a non-business day) on the first business day following transmission, except where a notice is received stating that such mail has not been successfully delivered. 

23. This Indemnification Agreement shall continue in effect regardless of whether you continue to serve as an Office Holder of the
Company. 
 24. This Indemnification Agreement may be executed in any number of counterparts, each of which shall be deemed an
original and enforceable against the parties actually executing such counterpart, and all of which together shall constitute one and the same instrument; it being understood that parties need not sign the same counterpart. The exchange of an
executed Agreement (in counterparts or otherwise) by facsimile or by electronic delivery in pdf format shall be sufficient to bind the parties to the terms and conditions of this Indemnification Agreement, as an original. 

The Board has determined, based on the current activity of the Company, that the amount stated in Section 5 is reasonable under the
circumstances, and that those events and circumstances specified in Schedule A are foreseeable in light of the Company’s activities as of the date hereof. 

  
 A-8 

 Schedule A 

All references in this schedule to the “Company” shall be deemed to refer to a Subsidiary or Affiliate as well, to the extent
that your service as an office holder, director, employee or board observer of the Subsidiary or Affiliate is at the request of the Company in the circumstances described in the preface of Section 1 to the Indemnification Agreement. 

1. The offering of securities by the Company and/or by a shareholder to the public and/or to private investors or the offer by the Company to
purchase securities from the public and/or from private investors or other holders pursuant to a prospectus, agreement, notice, report, tender and/or other proceeding, whether in Israel, the United States or abroad; 

2. Occurrences resulting from the Company’s public filings or omissions to make a public filing, delisting of shares, or buy-back of Company’s securities; 
 3. Occurrences in connection with investments the Company make in
other corporations whether before and/or after the investment is made, entering into the transaction, the execution, development and monitoring thereof, including without limitation, actions taken by you in the name of the Company as an Office
Holder and/or board observer of the corporation which is the subject of the transaction and the like; 
 4. The sale, purchase and holding of
negotiable securities or other investments for or in the name of the Company; 
 5. Actions in connection with an actual or anticipated
change in ownership, control or structure of the Company, its reorganization, dissolution, including without limitation, a merger, sale or acquisition of shares, or change in capital; 

6. Actions in connection with any actual or proposed transaction not in the ordinary course of business of the Company, including without
limitation, the sale, lease or purchase of any assets, subsidiary, operations and/or business, or part thereof, of the Company; 
 7. Actions
concerning the approval of transactions of the Company with officers and/or directors and/or holders of controlling interests in the Company, and any other transactions referred to in Section 270 of the Companies Law; 

8. Without derogating from the generality of the above, actions in connection with the purchase or sale of companies, legal entities, business,
securities or assets, and the division or consolidation thereof, including without limitation, any Tender Offer, Forced Sale of Shares, Arrangement and Compromise (as such capitalized terms are defined in the Companies Law) or any reorganization,
merger or consolidation of whatever kind or nature within the meaning of any law applicable to such claim or demand; 
 9. Actions taken in
connection with labor relations and/or employment matters in the Company and trade relations of the Company, including without limitation, with employees, independent contractors, customers, suppliers and various service providers; 

  
 S-A-1 

 10. Actions in connection with products or services developed and/or commercialized by the
Company, including without limitation, the performance of pre-clinical and clinical trials on such products, whether performed by the Company or by third parties on behalf of the Company, and/or in connection
with the certification, distribution, sale, license or use of such products, including without limitation in connection with professional liability and product liability claims and/or in connection with the procedure of obtaining regulatory or other
approvals regarding such products, whether in Israel or abroad and including without limitation, liabilities arising out of advertising or marketing, including without limitation, misrepresentations regarding the Company’s products and
unlawful distribution of emails; 
 11. Actions taken in connection with the intellectual property of the Company, and its protection,
including without limitation, the registration or assertion of rights to intellectual property and the defense of claims related to intellectual property, including without limitation, any assertion that the Company’s products violate,
infringe, misappropriate or misuse the intellectual property rights of any third party; 
 12. Actions taken pursuant to or in accordance
with the policies and procedures of the Company (including without limitation, tax policies and procedures), whether such policies and procedures are published or not; 

13. Approval of corporate actions, in good faith, including without limitation, the approval of the acts of the Company’s management,
their guidance and their supervision; 
 14. Claims of failure to exercise business judgment and a reasonable level of proficiency, expertise
and care in regard of the Company’s business; 
 15. Violations of laws requiring the Company to obtain regulatory and governmental
licenses, permits and authorizations in any jurisdiction; 
 16. Claims in connection with publishing or providing any information, including
without limitation, any filings with governmental authorities, on behalf of the Company in the circumstances required under applicable laws; 

17. Any claim or demand made under any securities laws of any jurisdiction or by reference thereto, or related to the failure to disclose any
information in the manner or time such information is required to be disclosed pursuant to any securities authority or any stock exchange disclosure or other rules, or any other claims relating to relationships with investors, debt holders,
shareholders and the investment community; or related to inadequate or improper disclosure of information to investors, debt holders, shareholders and the investment community, claims relating to or arising out of financing arrangements, any breach
of financial covenants or other obligations towards lenders or debt holders of the Company, class actions, violations of laws requiring the Company to obtain regulatory and governmental licenses, permits and authorizations in any jurisdiction;
actions taken in connection with the issuance of any type of securities of Company, including without limitation, the grant of options to purchase any of the same, or related to the purchase, holding or disposition of securities of the Company or
any other investment activity involving or effected by such securities, including, without limitation, any offering of the Company’s securities to private investors or to the public, and listing of such securities, or the offer by the Company
to purchase securities from the public or from private investors or other holders, and any undertakings, representations, warranties and other obligations related to any such offering, listing or offer or to the Company’s status as a public
company or as an issuer of securities; 

  
 S-A-2 

 18. Any claim or demand made by any lenders or other creditors or for monies borrowed by, or
other indebtedness of, the Company; 
 19. Any claim or demand made directly or indirectly in connection with complete or partial failure, by
the Company, or their respective directors, officers and employees, to pay, report, keep applicable records or otherwise, any state, municipal, federal, county, local, city or foreign taxes or other mandatory payments of any nature whatsoever,
including, without limitation, income, sales, use, transfer, excise, value added, registration, severance, stamp, occupation, customs, duties, real property, personal property, capital stock, social security, unemployment, disability, payroll or
employee withholding or other withholding, including without limitation, any interest, penalty or addition thereto, whether disputed or not; 

20. Any claim or demand arising out of dealings by the Company with third parties, including without limitation, agents, employees, customers,
suppliers, creditors or others; 
 21. Any claim or demand arising out of presentations or reports submitted or delivered (or not submitted
or delivered) to shareholders (whether current or prospective), customers or creditors of the Company or to any governmental entity or agency, including without limitation, relevant securities authorities or commissions; 

22. Any claim or demand made by purchasers, holders, lessors or other users of products of the Company, or individuals treated with or exposed
to such products, for damages or losses related to such use or treatment; 
 23. Review, approval and actions taken in connection with the
financial and tax reports of the Company, including without limitation, any action, consent or approval related to or arising from the foregoing, including without limitation, execution of certificates for the benefit of third parties related to the
financial statements; 
 24. Claims in connection with anti-competitive laws and regulations and laws and regulation of commercial
wrongdoing; 
 25. Claims in connection with breach of confidentiality obligations, acts in regard of invasion of privacy, including with
respect to databases, and acts in connection with slander and defamation; 
 26. Claims or demands made by any third party suffering any
personal injury and/or bodily injury and/or property damage to business or personal property through any act or omission attributed to the Company, or its employees, agents or other persons acting or allegedly acting on their behalf; 

27. Any administrative, regulatory or judicial actions, orders, decrees, suits, demands, demand letters, directives, claims, liens,
investigations, proceedings or notices of noncompliance or violation by any governmental entity, including without limitation, the Office of the Chief Scientist or the Investments Center of the Israeli Ministry of Industry, Trade and Labor, the
Israeli Antitrust Authority, the Israel Securities Authority, the United States Securities and Exchange Commission, 

  
 S-A-3 

 
or other person alleging the failure to comply with any statute, law, ordinance, rule, regulation, order or decree of any governmental entity applicable to the Company, or any of its businesses,
subsidiaries, assets or operations, or the terms and conditions of any operating certificate or licensing agreement; 
 28. Any action or
decision regarding Distribution; 
 29. An announcement, a statement, including without limitation, a position taken, or an opinion made in
good faith by an Office Holder in the course of his duties and in conjunction with his duties, including without limitation, during a meeting of the Board or one of the committees of the Board; 

30. An act or omission undertaken in contradiction to the Company’s Memorandum of Association or Articles of Association; 

31. Any action or decision in relation to work safety and/or working conditions; 

32. An act or omission undertaken in negotiating, signing and performing an insurance policy or any claim relating to a failure to maintain
appropriate insurance and/or adequate safety measures; 
 33. Any claim or demand made by a customer, supplier, contractor or other third
party transacting any form of business with the Company, in the ordinary course of their business, relating to the negotiations or performance of such transaction, or representations or inducements provided in connection therewith or otherwise. 

34. Any administrative, regulatory, civil or judicial actions, orders, decrees, suits, demands, demand letters, directives, claims, liens,
investigations, proceedings or notices of noncompliance or violation by any governmental entity or other person alleging potential responsibility or liability (including without limitation, potential responsibility or liability for costs of
enforcement, investigation, cleanup, governmental response, removal or remediation, for natural resources damages, property damage, personal injuries, or penalties or for contribution, indemnification, cost recovery, compensation, or injunctive
relief) arising out of, based on or related to (x) the presence of release, spill, emission, leaking, dumping, pouring, deposit, disposal, discharge, leaching or migration into the environment (each a “Release”) or threatened Release
of, or exposure to, any hazardous, toxic, explosive or radioactive substances, wastes or other pollutants and all other substances or wastes of any nature regulated pursuant to any environmental law, at any location, whether or not owned, operated,
leased or managed by the Company, or any of its subsidiaries, or (y) circumstances forming the basis of any violation of any environmental law, environmental permit, license, registration or other authorization required under applicable
environmental and/or public health law. 

  
 S-A-4 

 Exhibit C 

Confidentiality, Disclosure of Information and 

Assignment of Inventions Agreement 
 To:
Teva Pharmaceutical Industries Ltd. and its subsidiaries and affiliates (the “Company”) 
 Re: Proprietary Information, Non-Disclosure and Assignment of Inventions Agreement 
 The undersigned (“Executive”)
hereby acknowledges that he will have access to, certain proprietary information, inventions, commercial secrets and other confidential information of the Company and may participate in the development, planning or marketing of the Company’s
products, in connection with Executive’s employment under the Employment Agreement entered into between the Company and Executive dated November 6, 2019 (hereinafter, the “Employment Agreement”). In relation to such
confidential information Executive hereby undertakes as follows, in full knowledge that the force of this undertaking is in no way dependent upon the force of the Employment Agreement, is entirely independent from said agreement, does not in any way
constitute a concurrent obligation with the obligations defined in the Employment Agreement and has been a material part of the consideration of his engagement by the Company: 
  

	1.	 Proprietary Information and Non-Disclosure 

  

	 	1.1.	 Executive acknowledges and agrees that he will have access to or be involved in the planning, making or
development of, confidential and proprietary information concerning the business and financial activities of the Company or its property, business, dealings, clients, suppliers, people or entities that come into contact with them, their operational
methods, research or manufacturing process, plans and strategies, business plans, research projects, employees, marketing plans, supplier lists, customers, data, trade secrets, test results, formulas, processes, data and know-how, improvements, inventions, patents, application for patents, copyrights, trademarks, engineering specifications, product designs, technical information discoveries, studies, techniques, specifications,
computer programs (in source and object code), databases, products (actual or planned) and information contained in computers, preservation of information methods, disks, diskettes, drawings, plans, communications, prospectuses, reports, prices,
calculations, fees, work conditions in the Company or other agreement conditions which relate to the Company and documents of the Company. All such information, whether in documentary, written, oral or digital format, and whether received by
Executive as a result of his employment with the Company or brought to his attention in any other manner, shall be deemed to be and referred to as “Proprietary Information.” For purposes of this Confidentiality, Disclosure of
Information and Assignment of Inventions Agreement, the term “Company” shall include all entities within the Company Group (as defined in the Employment Agreement). 

“Proprietary Information” shall be deemed to include any and all proprietary information disclosed by or on behalf of the Company
irrespective of form, but excluding information that (i) was known to Executive prior to his association with the Company and can be so proven by Executive by documentary evidence; (ii) 

  
 C-1 

 
shall have appeared in any printed publication or patent of a third party or shall have become a part of the public knowledge except as a result of a breach of this Agreement by Executive; or
(iii) shall have been received by Executive from a third party having no obligation to the Company. 
 In addition, the term
“Proprietary Information” shall include information regarding salaries, bonuses and benefits paid or granted to Executive by the Company under the Agreement to which this Exhibit E is attached. 

 

	 	1.2.	 Executive agrees and declares that all Proprietary Information and rights in connection therewith are, and
shall be, the sole property of the Company and its assignees. At all times, both during the term of his engagement with the Company and thereafter Executive will keep in strict confidence and trust all Proprietary Information, and Executive will not
copy, transmit, reproduce, summarize, quote, publish and/or make any commercial or other use or disclose directly or indirectly any Proprietary Information or anything relating to it without the prior written consent of the Company, except as may be
necessary in the ordinary course of performing Executive’s duties in his engagement with the Company and in the best interests of the Company. 

  

	 	1.3.	 Executive recognizes that the Company received and will receive confidential or proprietary information from
third parties subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. At all times, both during the term of his engagement with the Company and thereafter,
Executive undertakes to hold and maintain all such information in strict confidence, and not to use or disclose any of such information without the prior written consent of the Company, except as may be necessary to perform his duties as an
Executive of the Company and consistent with the Company’s agreement with such third party. 

  

	2.	 Assignment of Inventions 

 

	 	2.1.	 Executive understands that the Company is engaged, involved or associated in a continuous program of
investment, research, development, production or marketing in connection with its business and that, as an essential part of his engagement with the Company, he may make new contributions to and create
know-how of value for the Company. 

  

	 	2.2.	 During the term of his engagement, Executive undertakes and covenants that he will promptly disclose in
confidence to the Company all inventions, improvements, ideas, themes, designs, original works of authorship, formulas, concepts, techniques, forecasts, test results and documentation, discoveries, models, drawings, tooling, schematics and other
diagrams, instructional material, notes, records, algorithms, operating procedures methods, systems, processes, compositions of matter, computer software programs, databases, mask works, and trade secrets, whether or not patentable, copyrightable or
protectable as trade secrets or under any other intellectual property right, that are made or conceived or first reduced to practice or created by him, either alone or jointly with others, in the course of his engagement with the Company and due to
his engagement with the Company (“Inventions”). 

  
 C-2 

	 	2.3.	 Executive agrees and represents, that all Inventions will be the sole and exclusive property of the Company
and/or its assignees and undertakes to act with respect to such Inventions in accordance with the Company’s applicable corporate policy. 

  

	 	2.4.	 To the extent relevant, Executive agrees to keep and maintain adequate and current written records of all
Inventions made by him (solely or jointly with others) during the term of his engagement. The records will be in the form of notes, sketches, drawings and any other format that may be specified by the Company. The records will be available to and
remain the sole property of the Company at all times and will be returned to the Company upon the termination of Executive’s employment or earlier at the request of the Company. 

 

	 	2.5.	 Executive hereby irrevocably transfers and assigns to the Company and/or its assignees and shall in the future
take all reasonable steps (including by way of illustration only, signing all appropriate documents) to assign to Company and/or its assignees without additional consideration to Executive (other than Executive’s salary and other benefits to
which he is entitled to as an employee of the Company (including without limitation, without any compensation or royalties in accordance with Sections 132 or 134 of the Patent and Design Act of 1967 (the “Patent Law”)): (a) all
worldwide patents, patent applications, copyrights, mask works, trade secrets and other intellectual property rights, titles and interests, in any Invention, including, without limitation, service inventions under Section 134 of the Patent Law,
and hereby further acknowledges and shall in the future acknowledge Company’s full and exclusive ownership in all such Inventions; and (b) any and all Moral Rights (as defined below) that he may have in or with respect to any Invention.
Executive also hereby forever waives and agrees never to assert any and all Moral Rights he may have in or with respect to any Invention, even after termination of his engagement with the Company. “Moral Rights” mean any rights of
paternity or integrity, any right to claim authorship of an invention, to object to any distortion, mutilation or other modification of, or other derogatory action in relation to, any Invention, whether or not such would be prejudicial to his honor
or reputation, and any similar right, existing under judicial or statutory law of any jurisdiction whatsoever, or under any treaty, regardless of whether or not such right is denominated or generally referred to as a “moral right.”

  

	 	2.6.	 Executive expressly waives all economic rights in the Inventions including without limitation any rights to
royalties from any intellectual property right (specifically including patent rights under Section 134 of the Patent Law) and any right to receive any payment or other consideration whatsoever. 

 

	 	2.7.	 Executive agrees to assist the Company in every reasonable way to obtain and enforce, for the benefit of the
Company and/or its assignees exclusive and absolute title, right, interest, patents, copyrights, mask work rights, and other legal protections for the Inventions in any and all countries. Executive will execute any documents that may be reasonably
requested of him for use in obtaining or enforcing such patents, copyrights, mask work rights, trade secrets and other legal protections. Executive’s obligations under this Section 2.7 will survive the termination of his engagement with
the Company; provided that the Company will compensate him at a reasonable rate after such termination for time or expenses actually spent by him at the Company’s request on such assistance. After the termination of Executive’s
engagement with the Company, any assistance 

  
 C-3 

	 	
requested by the Company or any of its assignees pursuant to this Section 2.7 shall take into account Executive’s obligations towards third parties. Executive hereby irrevocably
appoints the Company and/or its duly authorized officers and agents (including, without limitation, the chairman of the Board) as his attorney-in-fact to execute
documents on his behalf for this purpose and agrees that, if the Company is unable because of Executive’s unavailability, mental or physical incapacity, or for any other reason, to secure Executive’s signature for the purpose of applying
for or pursuing any application for any Israeli or foreign patents or mask work or copyright registrations covering the Inventions assigned to the Company in this Section 2, to act for and on Executive’s behalf to execute and file any such
applications and to do all other lawfully permitted acts to further the prosecution and issuance of patents, copyright and mask work registrations with the same legal force and effect as if executed by Executive. 

 

	 	2.8.	 Executive hereby acknowledge and agrees that the salary and other benefits provided to him under his Employment
Agreement constitute appropriate, full and fair consideration in connection with his employment with the Company, including, without limitation, with respect to this Agreement and including with respect to Executive’s undertakings under this
Section 2, and with respect to any Inventions created, conceived or reduced to practice or that may be created, conceived or reduced to practice by Executive, either alone or jointly with others, in the course of his employment with the
Company, all of which are assigned to the Company in accordance with this Agreement, and Executive hereby unconditionally and irrevocably waives any right that he may have to receive any additional payment or other consideration whatsoever to which
Executive may be entitled with respect to any Invention pursuant to any applicable law, in any jurisdiction, including (but not limited to) pursuant to Section 134 of the Patent Law, or any provision that may supersede it. In the event that for
any reason such right cannot be waived, Executive hereby assigns and transfers to the Company any such right Executive may have to receive any additional payment or other consideration whatsoever with respect to any Invention pursuant to any
applicable law, including the Patent Law, in any jurisdiction. 

  

	 	2.9.	 The provisions of this Section 2 shall survive termination or expiration of the Employment Agreement and
shall be and remain in full force and effect at all times thereafter. 

  

	 	2.10.	 Executive acknowledges that the Company has entered into the Employment Agreement in reliance on his
undertaking set forth in this Section, and that given his access to information regarding the Company, the provisions of this Section 2 are reasonable and necessary to protect the Company’s business and rights. 

 

	 	2.11.	 If any one or more of the terms contained in this Proprietary Information, Assignment of Inventions and Non-Disclosure Agreement shall for any reason be held to be excessively broad with regard to time, geographic scope or activity, the term shall be construed in a manner to enable it to be enforced to the extent
compatible with applicable law. 

  

	3.	 Miscellaneous 

 

	 	3.1.	 Governing Law. This Agreement shall be governed by and construed according to the laws of the State of
Israel. Any dispute arising under or relating to this Agreement or any transactions contemplated herein shall be resolved in accordance with Section 20.6 of the Employment Agreement. 

  
 C-4 

	 	3.2.	 Injunctive Relief. Any breach of this Agreement may cause irreparable harm to the Company, for which
damages would not be an adequate remedy, and therefore, the Company will be entitled to injunctive relief from any court of competent jurisdiction as such court so determines, restraining any violation or further violation of this Agreement by
Executive. The Company’s right to injunctive relief shall be cumulative and in addition to any other remedies provided by law or equity and without any requirement to post bond. 

  
 C-5 

 IN WITNESS WHEREOF, Executive has signed this Proprietary Information,
Non-Disclosure and Assignment of Inventions Agreement as of November 6, 2019. 
  

			
	EMPLOYEE
	
	              

	                                      
            	 	
	
	ACCEPTED AND AGREED:
	
	TEVA PHARMACEUTICAL INDUSTRIES LTD
	
	
                

	Name:	 	
	Title:	 	
	
	             

	Name:	 	
	Title:	 	

  
 C-6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}]]